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ABSTRACT
A Magnetic Resonance Approach to Neurodegeneration
by
Yin-Ching Iris Chen
Submitted to the Harvard-MIT division of Health Sciences and Technology
and MIT Department of Nuclear Engineering
on May, 1997 in partial fulfillment of the requirements for the
degree of Doctor of Philosophy in Radiological Sciences
The primary objectives of this thesis were to investigate and verify the
utility of magnetic resonance techniques to probe neurodegenerative
processes. We focused primarily on Parkinson's disease (PD). We
demonstrated how various factors could alter the accuracy in estimating the
absolute metabolite concentration by using computer simulation. We found
that it would be difficult to obtain accurate relaxation times T, and T2 due
to the problems of spectral overlap , macromolecular contamination and J-
coupling effects. In estimating the metabolite concentration, we found that
the errors propagated from the T2 errors are more critical than the T,
errors. In human study, we found that PD patients' striatal lactate level
was elevated 59% than the normal controls (p < 0.004). We also found a
significant lactate asymmetry in the 2 striata, which is significant higher in
the PD group (64.51% increase, p < 0.05) in the "big side". However, we
did not have similar finding in the animals of PD model. However, the
neuronal marker N-acetylaspartate (NAA) in these animals showed a
significant decrease in the striatum ipsilateral to the lesioning (9.61%, p <
0.0003). To assess the neuronal activity by using pharmacological MRI
(phMRI), we used D-amphetamine and CFT as our specific dopaminergic
ligands. We have shown that 1) the BOLD signal change delineated to the
blood pCOz and global blood pressure changes, 2) phMRI response is
regionally specific to those brain areas with high dopaminergic
innervation, 3) phMRI response correlates the "C-CFT binding via PET,
4) phMRI time course correlates the dopamine release assessed by
microdialysis. We tested the phMRI technique on 3 groups of animals. We
showed the phMRI responses were symmetric in the normal control rats,
unilateral ablated in the unilateral dopaminergic denervated striatum, and
restored right at the graft site in the dopaminergic cell transplanted rats.
In conclusion, the data presented in this thesis demonstrate the ability of
using MR technique to explore the neurodegenerative processes and could
elucidate treatment strategies and benefit the patients suffering from
neurodegenerative diseases.
Thesis Supervisor: Bruce Jenkins, Ph.D.; Department of Radiology, Massachusetts
general Hospital, Harvard Medical School.
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Chapter 1 Background --- Why could MR be
useful for study of neurodegeneration?
In this thesis, we demonstrate the use of magnetic resonance (MR) as
a tool to investigate neurodegenerative diseases of the basal ganglia.
In order to answer the question of whether or not magnetic
resonance is a useful tool for the investigation of the
neurodegenerative processes, we start by defining possible
mechanisms of neurodegeneration and then explain MR techniques
may be employed to verify the hypotheses. The overall outline is:
* review of the basal ganglia system,
* review of hypotheses concerning the mechanisms of basal
ganglia degeneration,
* demonstrations of MR to investigate the neurodegenerative
process.
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Review of the basal ganglia system:
This section is a brief review of the basal ganglia, including the
neuronal anatomy and the neural circuits involved in the basal
ganglia function. In addition, this section will discuss the possible
mechanisms involved in disorders of the basal ganglia such as
Parkinson's disease (PD) and Huntington's disease (HD).
The neuronal network:
The question of how the brain works has. never been fully answered.
However, scientists have found their ways to explore the possible
mechanisms of brain function. The brain is comprised of hundreds of
billions of neurons. Groups of neurons compose suborgans of the
brain. How the individual neurons talk to each other has never been
easily answered. In short, neurons rely on stereotyped electrical
signals and chemical signals to communicate. The interconnections of
neurons integrate and play out the functions. Two types of
membrane potential signals are used by neurons: localized potentials
and action potentials. The localized potentials are only effective in a
very short distance and the neurons have to rely on the action
potentials to transmit signals over long distances (via axons). The
bridge for individual neurons to talk to each other is primarily via
neurotransmitters and their corresponding receptors. The arrival of
the action potentials at the axonal terminals causes the release of
neurotransmitters from the presynaptic neurons. The binding of the
neurotransmitters to their corresponding receptors can modulate the
electrical potentials on the postsynaptic neuronal membrane.
Different types of neurons possess different kinds of
neurotransmitters and receptors, which may potentiate or inhibit the
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formation of the action potentials on the postsynaptic neurons
(excitatory post synaptic potential (EPSP) or inhibitory post synaptic
potential (IPSP)). Based on the precise balance between the
excitatory and inhibitory interactions, the neuronal signals can be
modulated and transmitted.
The basal ganglia network:
The basal ganglia is a submodule of this complicated neuronal
network system. Although the complete mechanism of how the basal
ganglia function is yet to be determined, scientists have successfully
mapped out some neurotransmission routes. Based on these
neurotransmission routes, numerous hypotheses have been proposed
to reveal the role basal ganglia may be playing in brain function.
The basal ganglia may act as a self-regulated current-regulation
center to modulate the cortical activities. Further elaboration of this
current regulation theory (described below) may be applied to help
solve the etiologic mysteries of some of the basal ganglia relative
disorders, such as Parkinson's disease (PD) , Huntington's disease
(HD), hemiballismus, athetosis, etc. Let's take a closer look of the
basal ganglia.
Terminology of basal ganglia subunits:
The traditional term of "basal ganglia" refers to the deep gray matter
buried inside the cerebrum: caudate nucleus (CA), putamen, (internal
/ external) globus pallidus (GPi/GPe), subthalamic nucleus (STN), and
substantia nigra (SN). Because the caudate nucleus and putamen
share the same embryological origin, these two organs are generally
referred as the neostriatum or striatum. However, the nucleus
accumbens, which is the fusion part between caudate nucleus and
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putamen, is generally referred to as part of the limbic system but not
striatum. The putamen and globus pallidus comprise the lenticular
nucleus because of their lens like shapes. The combination of the
lenticular nucleus and the neostriatum is called the corpus striatum.
Basal ganglia circuit theory:
The striata basically form C-shaped courses along the lateral
ventricles and receive a broad range of signals from various cortical
areas. Although the striatum is relatively small in volume compared
to the cerebral cortex, the topographical innervation pattern from
and to the cortical areas has been mapped out by immunohistologic
techniques. Generally, the primary afferent neurotransmitter of the
striatum is glutamate. The caudate nucleus receives glutamatergic
input primarily from the prefrontal cortex and thus is thought to
have its major role in cognitive functions; while the putamen
primarily receives the glutamatergic input from the somatosensory
and motor cortex and thus its involvement in motor functions. The
excitatory cortico-striatal glutamatergic neurons set the basic tone of
the striatal neuronal firing rate. The striatum then serves as a relay
or modulation center which can integrate or modulate the
glutamatergic input signal by interactions with other
neurotransmitters, such as dopamine, serotonin, etc., through several
suborgans of basal ganglia. The signals from basal ganglia finally
reach thalamus and are relayed back to the cerebral cortex via
glutamate.
In order to understand how the basal ganglia are involved in motor
activity, we may simplify the complicated cortical-striatal-thalamic-
cortical route as shown in figure 1-1. As shown in the figure, both
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the striatum and STN receive excitatory glutamatergic input from
cortex and they also share the GPi as the main output node to the
thalamus (GABA, inhibitory) which then relays the signal back to
cortex (glutamate, excitatory). The cortical-STN-GPi route is of short
fast latency to inhibit unwanted motions and thus maintain the
posture. The cortical-striatal-pallidal-thalamic route is of long
latency with a tendency to inhibit the activity in GPi and thus to
disinhibit the desired motor activity. [1]
Figure 1-1 The two parallel disynaptic pathways from cortex to
globus pallidus. The solid arrow indicates an excitatory pathway and
the open arrow indicates an inhibitory pathway. GPe: globus pallidus
external, GPi: globus pallidus internal, SNr: substantia nigra pars reticulata,
STN: subthalamic nucleus.
The long latency circuit can be further divided into 2 parallel
pathways: the direct versus the indirect pathway ( figure 1-2). Each
segment has its particular neurotransmitters such as GABA,
substance P (SP), enkephalin, etc., as specified in figure 1-2 and they
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are mainly inhibitory substances. According to this kind of
neuropathway layout, the direct pathway is essentially the positive
feedback route while the indirect pathway is the negative feedback
route. Based on the basal ganglial circuit theory, hypokinetic
disorders, such as Parkinsonism can be the result of an overactive
'indirect' pathway while hyperkinetic disorders, like Huntington's
disease and hemiballismus, could be due to an underactive 'indirect'
pathway. [2,3,4,5] This simplified circuit theory provides a plausible
mechanism regarding movement disorders and also provides
valuable therapeutic strategies. Subthalamotomy has been
performed in PD patients to improve parkinsonism. [6,7] Pallidotomy
and thalamotomy (VA/VL) have been performed in PD patients to
reduce some of the side effects caused by the dopamine replacement
therapy ( "wearing-off" and "on-off" effects) and the occurrence of
dyskinesias caused by levodopa.
However, some of the clinical findings from the stereotaxic surgery
in Parkinson's disease have contradicted this theory. For example, a
thalamotomy, which might be expected to increase motor disability
according to the circuit theory, does not worsen movement in clinical
trials. [8] This may only suggest that the basal ganglia function is far
more complicated then the simple circuit theory presented and the
etiology of the neuronal degeneration in the striatum is far from
understood.
The nigro-striatal dopaminergic neurons seem to play an important
role in modulation of the main afferent glutamatergic signal.
Dopamine can either reduce the presynaptic neuronal activity (via D2
autorecepters), enhance the postsynaptic neuronal activity (via Dl
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receptors, mainly on the direct pathway), or inhibit the postsynaptic
neuronal activity (via D2 receptors, mainly on the indirect pathway).
The pathologic finding in idiopathic Parkinsonism is that there is a
tremendous amount of cell loss in the substantia nigra pars
compacta. The evidence from the postmortem studies on the
patients with idiopathic Parkinson's disease showed that the onset of
the parkinsonism did not show up approximately to 80-90% neuronal
loss in the SNc. [9,10,11] An animal model of parkinsonism which
uses the selective dopaminergic neurotoxin 6-hydroxydopamine (6-
OHDA) to interrupt the nigro-striatal dopaminergic pathway in rats
also demonstrated similar results. [12] The reasons why the nigral
cells die and how the insufficient dopamine concentration in the
striatum causes the dysfunction of the striatum are still unclear.
Several hypotheses have been proposed in an attempt to explain
these neuronal degeneration processes. The next section will discuss
some of the most popular hypotheses.
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Figure 1-2 Basal ganglia motor circuit -- direct versus indirect
pathways. Solid arrow indicates excitatory pathway and open arrow
indicates inhibitory pathway. The direct pathway is a positive
feedback loop and the indirect pathway is a negative feedback loop.
DA: dopamine, Enk: enkephaline, Glu: glutamate, GPe: globus pallidus external,
GPi: globus pallidus internal, SNc: substantia nigra pars compacta, SNr:
substantia nigra pars reticulata, STN: subthalamus nucleus, SP: substance P.
Possible etiologic hypotheses of basal ganglia depeneration
Mitochondrial energy impairment;
This hypothesis postulates that impairment of the mitochondrial
electron transport chain either directly or indirectly causes the cell
death in the substantia nigra. The evidence for this was discovered
accidentally in humans who had injected the street drug 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP), which was a contaminant
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of synthetic heroin analogue. The drug abusers who received MPTP
developed symptoms resembling idiopathic Parkinson's disease.
Further studies on MPTP discovered that this compound has the
potential to destroy the dopaminergic neurons in the substantia nigra
pars compacta (SNc) in human, primates, and some other animal
species. Actually, MPTP is not neurotoxic but its metabolite 1 -
methyl-4-phenylpyridinium ion (MPP') is. MPP' can inhibit
complex I (NADH dehydrogenase) in the mitochondrial electron
transport chain. Consequently, a decrease in the NAD+/NADH ratio
and an increase in the conversion rate of pyruvate to lactate are
expected and were observed in cell culture studies by Vyas el. al.
[13]
The key enzyme required to oxidize MPTP is the monoamine oxidase
subtype B (MAO-B), which is located on the astrocytes. MPTP is
oxidized by MAO-B to the intermediate substance MPTP +, and then
subsequently oxidized to MPP'. This metabolite MPP + is then
released from the glial cell and freely diffuses into the extracellular
space. Since MPP + is a substrate of the dopamine reuptake protein, it
can be transferred to the substantia nigra through the dopamine
reuptake pathway. MPP ÷ is finally accumulated inside the
mitochondrial matrix to inhibit the action of complex I and thus
causes the nigral cells to die. [14,15] Inspired by the MPTP/MPP +
findings, researchers have proposed that the neuronal degeneration
in idiopathic parkinsonism may be caused by some environmental or
endogenous toxins which may induce similar damage as MPP + does in
the mitochondrial electric transport chain in the SNc, possibly
through the MAO-B/dopamine reuptake pathway. If MAO-B is really
involved in idiopathic parkinsonism, using MAO-B inhibitors may be
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able to postpone the neuronal degenerative process. Clinical trials to
treat PD patients with L-dopa conjugating with deprenyl, the
selective and long-lasting MAO-B inhibitor, showed up to 56%
improvement in the disability score. [16,17] This clinical evidence
supported the hypothesis that the etiology of the idiopathic
parkinsonism may be related to mitochondrial energy stress.
However, other studies showed little effect. The latter finding may
be more consistent with the observation that by the time someone is
diagnosed with PD, 80 - 90% of the nigral dopamine neurons are
already dead.
Free Radicals:
As mentioned in the mitochondrial energy impairment section, MPP'
will interrupt the activity of NADH dehydrogenase in the electron
transport chain. However, some of the researchers suggest that the
mechanism of toxicity of MPP + is not to cause the interruption of the
electron transport but to generate oxygen radicals (superoxide) while
the electron transport is blocked at the stage of complex I. This free
radical theory is supported by the evidence of reduced levels of
glutathione and other antioxdants in substantia nigra and other brain
areas after the MPTP neurotoxicity. [18,19] Further evidence is
provided by studies showing free radical scavengers and anti-
oxidants can provide neuroprotection in animal model of MPTP /
MPP + toxicity. [20,21] However, further studies showed that there is
no detectable increase in lipid peroxidation [22] and there is a
mismatch between the degree of inhibition in the NADH
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dehydrogenate and the rate of superoxide formation. [23]
Nonetheless, all of the evidence suggests that free radical formation
may not be the primary cause of neurotoxin of MPP' but it ma y
accelerate the damage done by the cessation of mitochondrial
respiration.
Iron accumulation:
Several studies of post-mortem brains of the PD patients have
reported an abnormal increase in iron concentration. Iron is an
important trace element for electron transport, enzymatic catalysis
and neuronal development [24] and the disturbance of the iron
homeostasis may lead to neuronal dysfunction. Therefore, the
finding of high nigral iron concentrations in PD patients may suggest
that iron is involved in the pathogenesis of PD. Several groups have
suggested that iron may prompt free radical formation and also
catalyze lipid peroxidation, which may subsequently lead to neuronal
death. However, from post-mortem studies with human brains, the
abnormal nigral iron levels were only found in the severely affected
PD patients but not in mildly affected PD patients. [25] And
histochemical studies in rats with 6-OHDA lesions, a typical animal
model of PD which is able to induce neuronal degeneration in
SNc/VTA area, showed a substantial increase in Fe staining in the
ipsilateral SNc/VTA areas. There were no changes in the
contralateral side. [26] These data suggested that the high iron level
in SNc may be a secondary effect of the neurodegenerative process.
Although up to now how and why the iron accumulates in the SNc is
still unclear, Oestreicher proposed 3 possible mechanisms: 1) iron
may be associated with the infiltrating reactive glial cells; 2) loss of
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the dopaminergic neurons in the SNc may cause disregulation of the
nigral iron homeostasis; 3) 6-OHDA lesions lead to the dysfunction of
the blood-brain-barrier.
What MR can do for the study of neurodepeneration
As we discussed in the previous section, different hypotheses have
been proposed in an attempt to explain the neuronal degeneration in
PD. Among the 3 most popular hypotheses, we found that the energy
impairment theory may be the most plausible one in that it has the
most direct evidence. The first part of this thesis will search for
appropriate evidence to support this hypothesis in PD patients by
using magnetic resonance spectroscopy (MRS) to investigate cerebral
metabolites such as the energy impairment marker of lactate and the
neuronal marker of N-acetylaspartate. In addition to the patient
group, a well characterized animal model for PD, the specific selective
lesioning in the nigro-striatal dopaminergic neurons by the toxin 6-
hydroxy-dopamine (6-OHDA), provides us a further opportunity to
investigate the hypothesis that insufficient dopaminergic innervation
in the striatum can induce striatal neuronal stress. The iron
accumulation theory can also be investigated by monitoring AR2*
changes. We therefore propose to use MR as a tool to investigate the
question of whether or not in these 6-OHDA lesioned animals there is
any disturbance of the striatal metabolite levels, or any change in the
hemodynamic properties. Furthermore, we will test the possibility of
using functional MRI (fMRI) to observe the coupling between the
transmitter-receptor activity and the corresponding neuronal
response. We will propose to use pharmacological stimulation to
22
make this neuronal coupling visible and thus we will propose to call
this novel technique as pharmacological MRI (phMRI).
Before we can go further in to the experimental set up, we have to
answer several questions:
Is 'H Magnetic resonance spectroscopy (MRS) useful to
investigate the mitochondrial energy stress theory?
The individual 'H nucleus under a steady magnetic field will
experience a slightly different magnetic field due to the shielding
effect set up by the surrounding electrons. This perturbation of the
magnetic momentum, called chemical shift, enables us to detect
nuclei of different molecular structures via MR spectroscopy. There
are a number of cerebral molecules which are 'H magnetic resonance
visible [27,28]. Table 1-1 shows a partial list and the properties of
these molecules. Among these MR visible molecules, the most
prominent one is N-Acetylaspartate (NAA), which is believed to be
the marker of normal neurons because it is found almost exclusively
in neurons but not glial cells [29,30]. The spectral peak labeled Cr at
3.03 ppm is composed of both Cr and PCr. When energy impairment
occurs, one expects hydrolysis of PCr to Cr and the total resonance
intensity would not change assuming the relaxation times are the
same for both molecules. Creatine is thus usually taken as an
internal standard when absolute or relative quantification of other
molecules is necessary.
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Compound Structure Relevance to Neurodegeneration
(Chemical Shifts and Approximate
Human Brain Concentration)
N-acetylaspartate (NAA)
2.023 ppm (CH 3)
2.52 ppm (3CH) 2.70 ppm q3'CH)
=8mM
Neuronal Marker
Higher Concentration in Grey Matter
Compared to White Matter
Aspartate (asp) - Excitatory neurotransmitter
2.69 ppm (1CH) C--CH2-CH--C
2.82 ppm $'CH) NHI IO May possess excitotoxic potential2.82 ppm (@'CH) NH2
=2 mM
CHa Also composed of other trimethylamines
Choline / Phosphocholine (CHO) HO-CH2 -CH 2  H3
3.23ppm (CH) 3  I May represent lipid breakdown products
- 1.6 mM CHa and/or gliosis
Creatine /Phosphocreatine (Cr/PCr) C--CH2 -N-C-N Hs Peak represents sum of total creatine.
3.95 ppm (CH) CHa NH Supplies phosphate for conversion of
=7.69mM ADP to ATP in creatine kinase reaction.
g-aminobutyric acid (GABA) Inhibitory Neurotransmitter
1.91 ppm (3CIH) NH- H 2 -CH 2  H 2  Large fraction of basal ganglia neurons
2.31 ppm (roCH) 3.02 ppm (CH22 H 2 O are GABAergic
S3 mM
CH 2 H Fuel for the brain - most ND conditions
o-D-Glucose 4H /1 cH show hypo-metabolism of glucose
3.2-4.1 ppm ([2-6]CH)
5.32 ppm ([1] CH) IO H Detectable in 2D studies in vivo but
=0-3 mM OH OH quantitation at low field strengths nearly
impossible except potentially peak at
5.32 ppm.
Major excitatory neurotransmitter in brain.
Potential Excitotoxin.
Quantifiable at high fields
Source of glutamate for neurotransmission
Quantitation problems as hard as for
glutamate.
OH OH
I I Possible osmoregulator.
Myo-inositol ([mI) H I  Precursor of inositol polyphosphate (IP 3)
.54 ppm ([1,3]CHH OH C intracellular messengers.
I I
OH H
Lactate H End product of anaerobic glycolysis
1.33 ppm (13 Cl-I) <- CH3
'0.5 mM 0 
"  Barely detectable in normal brain.
Table 1-1. Common neurochemicals observable in proton MRS
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Table 1-1 indicates that MRS would allow us to evaluate many
factors of the cerebral status during physiological challenge or
following events relevant to neurodegeneration. By monitoring the
amount of NAA (2.023ppm), one can determine the survivability of
the neurons under neurotoxic challenge. By monitoring the lactic
acid amount (1.33 ppm), one can investigate the degree of energy
stress the neurons are experiencing. This lactate measurement can
serve as an index to support the energy impairment theory in
neuronal degeneration as we mention earlier. Furthermore, by
monitoring the glutamate/glutamine (Glx) level, one can investigate
the possibility that the vulnerability of the striatal neurons after
dopaminergic stimulation may be caused by glutamate toxicity.
Overall, although MRS possesses some technical difficulties related to
the insensitivity of MR in general, such as the limitation in the
spatial, temporal, and chemical resolutions, which are beyond the
scope of this text to explain, it still provides us an excellent
opportunity to investigate cerebral events at the molecular level. In
this thesis, we will test the hypothesis that PD may be the result of
energy impairment in the electron transport chain. And we would
like to apply the MRS technique to PD patients to investigate whether
there is any abnormality in the cerebral lactate levels. Furthermore,
we would like to investigate any other abnormality of the 1H spectra
possibly found in this PD patient group.
What can functional MR technique do to investigate the
neurotransmission system?
Neuronal activity is coupled with changes in regional cerebral blood
flow (rCBF) [31], regional cerebral volume (rCBV) [32,33], blood
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oxygenation [32,34], and metabolism [35,36]. Results of positron
emission tomography (PET) studies indicate there is no or little
change in oxygen consumption during neuronal activity [32,34,36].
Based on the rationale that changes in rCBF will be 2-4 times larger
than changes in rCBV [37], the venous oxygenation will increase from
base line level 30% to 75% due to neuronal activity with constant
oxygen consumption [32,34,36]. Kwong et. al. demonstrated that
these hemodynamic changes are detectable by using magnetic
resonance techniques without exogenous contrast agents [38]. In the
baseline condition, deoxyhemoglobin, which is paramagnetic, sets up
a magnetic field gradient at the interface of the vessels and the
surrounding tissues. This inhomogeneous field is manifested as a T2*
effect and will decrease the magnetic resonance signal intensity.
While in the activation state, the increase in the concentration of
oxyhemoglobin and a decrease in the concentration of paramagnetic
deoxyhemoglobin causes an increase in the MR signal intensity due
to a reduction in T2* effect. The concept of detecting the oxygenation
changes by using MR is also known as the BOLD effect (Blood
Oxygenation Level Dependent) [39] has been widely applied to
investigate the brain functions and is thus called functional MRI
(fMRI). Although fMRI has been proved to be powerful to map out
neuronal systems, such as language[40,41], the visual system [42,43],
auditory system [44], etc., the question of whether fMRI has the
ability to observe the in vivo neuronal activity at the
neurotransmitter level is yet to be determined. Spatial, temporal
resolution and the signal to noise ratio (SNR) are the main issue for
MR to go down to the in vivo molecular level to follow the neuronal
activation. However, since neuronal activity is coupled with rCBF and
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rCBV, there is a possibility of investigating the neurotransmitter
activity by following the corresponding hemodynamic responses. In
this thesis, we propose to investigate the hemodynamic properties of
the dopaminergic neurotransmission system in response to
pharmacological stimulation. We propose to name this new
application of functional MRI as pharmacological MRI or phMRI.
With the aid of phMRI technique, we may monitor the remaining of
the dopaminergic innervation in the elderly brain to evaluate the
possibility of progressive PD before any symptom shows up.
Based on the background regarding basal ganglia degeneration and
the ability to use MR to study Parkinsonism, in the following
chapters this thesis will discuss:
* Development of appropriate MR techniques to study
neurodegeneration
* Human studies of PD using MRS
* Animal studies of PD models using MRS and hemodynamics
measurements.
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Error Analysis of the Cerebral
Metabolite Concentrations in 1H
Magnetic Resonance Spectroscopy
Introduction
Over the past decade 1 H Magnetic Resonance spectroscopy ( 1H MRS)
has developed into a powerful tool for investigation of cerebral
metabolites in vivo and in vitro. Comparisons using both relative
amplitudes among the metabolite peaks [1,2] as well as the absolute
metabolite concentrations [3,4,5] have been proposed to monitor the
neurochemical changes during cerebral pathologies or physiological
challenges. However, the absolute metabolite concentrations
reported from different groups are not always consistent. For
instance, the NAA concentration could be as low as 4 p4 mol/g [6] or
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Chapter 2
as high as 17 .t mol/g [8] and the creatine values have been reported
between 7.7 p. mol/g [6] and 10 pt mol/g [8]. One criterion for
measurement of an accurate metabolite comparison, whether it is
relative or absolute metabolite concentration estimate, is the
existence of an internal reference metabolite peak whose amount
should remain constant during various physiological and
pathophysiological conditions. Creatine [7,8] and unsuppressed water
signals are two of the most popular spectral peaks used as the
internal standards. However, uncertainty in the invariance of the
internal standard makes the relative concentration comparison less
reliable. Several investigators have proposed using external
standards such as MnC12-doped [9] water or trimethylsilylethanol
(TSE) [10,11] with known T, and T2 values and concentrations. This
approach also has some difficulties, such as the distortion of the
signal amplitude due to the possible field inhomogeneity (BI field
and static field B0 ) when the external standard sample is placed
beside the head. Nonetheless, if the accurate absolute metabolite
concentration is achievable, it is highly desirable because it would
allow one to:
1) make inter-subject comparisons,
2) make physiologic parameter estimations, such as
CMRglucose calculations.
In this chapter, we will discuss the possible factors which may alter
the accuracy of the metabolite amounts estimated from 1H MR
spectroscopy.
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Method to Estimate the Cerebral Metabolite Concentrations
from 1H MR Spectroscopv:
In principle, different chemical groups may experience slightly
different magnetic fields due to shielding by electrons and thus
express themselves at different MR spectral positions called chemical
shifts. The chemical shift is invariant as expressed in ppm but is
proportional to the magnetic field strength as expressed in Hz. Like
fingerprints, most of the chemical groups have their own chemical
shift values and are represented as resonances centered at the
specific chemical shift locations (ppm or Hz). Depending upon the
scalar coupling effects among different chemical groups of the same
molecule, the lines may be split into doublet, triplet, or even higher
order multiplicities. Over the past several decades, most of the
observable cerebral spectral peaks from 1H MRS have been
identified and assigned to their corresponding chemical groups.
Table 2-1 is a list of most of the major cerebral metabolites which
are 1H MRS detectable. From basic magnetic resonance spectroscopy
theory, the signal intensity of a singlet spectral peak from a spin-
echo experiment should follow the expression shown in equation 2-1:
TR TE
SIAa = MoA(1- exp(-  ) )exp(- ) (2-1)
T1Aa T2Aa
where
SIAa = signal intensity from the spectral peak 'a' of molecule A
MoA = proton density of molecule A
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c NAa X [A] (2-2)
NAa = number of protons in this spectral group 'a' of molecule
A,
[A] = concentration of molecule A.
And
TR TE
MoA(1-exp(- ) )exp(- )
SIAa TAa T2Aa (2-3)
SI TR TEIBb MoB(1-exp(- ) )exp(- )
T1Bb T2Bb
TR TE
NoA[A](1- exp(- ) )exp(- )
T1Aa T2Aa (2-4)
NoB[B](1- exp(- ) )exp(- )
TIBb T2Bb
where, a and b are the 2 spectral peaks from the 2 different
molecules A and B.
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Compound Structure Relevance to Neurodegeneration(Chemical Shifts and Approximate
Human Brain Concentration)
N-acetylaspartate (NAA) O- PO
2.023 ppm (CH) 0 C-- Hz- 2 Neuronal Marker
2.52 ppm (CH) 2.70 ppm O'CH) NH
= 8mM Higher Concentration in Grey MatterC=O Compared to White Matter
Aspartate (asp) Excitatory neurotransmitter
2.69 ppm (~CH) C -CH 2 -CH&G- "
2.82 ppm (13'CH) 0 H• 0 May possess excitotoxic potential
=2 mM
CH 3  Also composed of other trimethylaminesCholine / Phosphocholine (CHO)
3.23ppm (CH3  H HH May represent lipid breakdown products
= 1.6 mM H3  and/or gliosis
Cratin3.03 / Phosphocreatine (Cr/PCr) O C -- CH -N--C- NH 3 Peak represents sum of total creatine.
3.95 ppm (CHO) ,H 3 iH Supplies phosphate for conversion of
=7.6mM ADP to ATP in creatine kinase reaction.
g-aminobutyric acid (GABA) Inhibitory Neurotransmitter
1.91 ppm (1 CH2 ) NH -CH 2 -CH 2 -CH 2-C O Large fraction of basal ganglia neurons
2.31 ppm (tcCH 2) 3.02 ppm (TCH2) 20 are GABAergic
S3 mM
CH 20H Fuel for the brain - most ND conditions
a-D-Glucose H H show hypo-metabolism of glucose
3.2-4.1 ppm ([2-6]CH) I
5.32 ppm ([1] CH) OH H Detectable in 2D studies in vivo but
-0-3 mM OH quantitation at low field strengths nearly
I I impossible except potentially peak at
H OH 5.32 ppm.
Glutamate (Glu) Major excitatory neurotransmitter in brain.
2.06 ppm 'CH) 2.3.76 ppm (CH) C H 0 Potential Excitotoxin.
6-2.10 ppm 'CH) 3.76 N+H3  Quantifiable at high fields
- 6 - 10 mM
Glutamine (Gln) Nl 2 -H -CH2 0- Source of glutamate for neurotransmission
2.14 ppm q3CH2) OC-CH 2 CH2 CH -C-
2.46 ppm (ICH2) 3.78 ppm (aCH) 0 0 Quantitation problems as hard as for
-3 mM glutamate.
OH OH Possible osmoregulator.
Myo-inositol (ml) OH H
3.54 ppm ([1,3]CH) L/ i Precursor of inositol polyphosphate (IP3)
5 mM NH\H OH/ J intracellular messengers.H I OH
I I
OH H
Lactate H End product of anaerobic glycolysis
1.33 ppm CH3) H Barely detectable in normal brain.
-0.5 mM
Table 2-1 Common neurochemicals observable in proton MRS
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In theory, if the molar concentration of chemical A is known, then
the absolute concentration of chemical B can be estimated with the
knowledge of T, and T2 values of both of the spectral groups a and b:
TR TE(1 - exp(- ) )exp(- )
[B] = SIBb A]NAa T1Aa T2Aa (2-5)
SIAa NBb (l-exp(- ) )exp(- TE)
TlBb T2Bb
For in vivo cerebral spectral studies, the molar levels of cellular
water and creatine are relatively stable and are usually taken as the
internal spectral standards, to map out the amounts of other cerebral
metabolites. However, according to equation (2-5), the
measurements of absolute metabolite concentrations are only
feasible when the measurements of the spectral signal intensities
and T I/ T2 values are accurate. In the following sections, we will
discuss the possible errors which may propagate into the absolute
concentration measurements.
Spectral quality:
Spectral Overlap
The spectral peaks can be expressed as Lorentzian lines centered at
their corresponding chemical shifts (ppm or Hz). The line width of
the Lorentzian line is proportional to the relaxation rate R2* (R2* =
1/ T2*, Av 1/2 = 1/HT 2*) which is composed of several factors:
R 2= R2 + XR 2n (2-6)
n
38
where R2 is the intrinsic spin-spin relaxation rate of this particular
molecule in the magnetic field and R2ns are some external factors
which can accelerate the relaxation rate, such as the inhomogeneity
of the magnetic field, flow rate, etc. In the practical world, there are
several factors which may lead to magnetic field inhomogeneity,
such as an imperfect shim of the magnetic field caused by sudden
changes of the magnetic susceptibility Xm close to the interface of
two different tissue compartments (e.g., grey-white matter
boundary, brain-CSF or brain-air sinus interface, etc.). The bigger
the relaxation rate is, the broader the Lorentzian line width will be.
The typical line width of 1H MR cerebral spectra can as low as 2 Hz
in small single voxel experiments. However, since the chemical shift
distance (Hz) between 2 chemical groups is proportional to the
strength of magnetic field, the 1H spectra from a low field clinical
magnet (0.5 ~ 1.5 T) may not allow one to resolve one individual
spectral peak from the adjacent ones at a given broad spectral line
width. Prior work using 2D COSY experiments has demonstrated that
there are many overlapping 1H chemical shifts which cannot be
resolved without the use of the 2D technique [12]. The spectral
composition may be even more complicated if some of the spectral
peaks are J-coupled and split to various multiplicities which can
undergo phase modulation as a function of echo time (TE). We will
discuss this phenomenon later. General speaking, one can reduce the
spectral line width with a better shim of the magnetic field , and
with care to the choice of the imaging voxel cover as few
heterogeneous tissues as possible, and to keep the voxel as far away
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from interfaces such as sinuses with huge magnetic susceptibility
differences as is possible.
Signal to Noise Ratio (SNR)
The concentrations of cerebral metabolites are generally in the
millimolar range while the cellular water/lipid contents are in the
molar range. To detect these concentration differences in the 1H
MRS measurement, the signal from water or lipid will be thousands
of times bigger than the signal from the cerebral metabolites.
Therefore, water/lipid suppression has to be applied to make the
cerebral metabolite signals visible. However, imperfect water/lipid
suppression can still lead to some problems. As water and lipid are
present in such huge quantities compared to the cerebral
metabolites, reduction of the signal intensity to only one tenth of the
original water/lipid amount still leaves the water or lipid signal
much bigger than the metabolite signal. As most of the receiver bits
would be used to digitize the massive water/lipid signals, there
would not be enough dynamic range to digitize the tiny spectral
signals of cerebral metabolites. In other words, the signal to noise
ratio (SNR) of the metabolites will be too small to detect the
metabolite signals. Furthermore, as the shoulders of the water/lipid
peaks may extend over quite a wide range of chemical shift with
non-negligible amplitude, this may lead to problems like baseline
shift and phase distortion of the metabolite peaks. So, the lower the
SNR the 1H MR spectrum has, the more complicated the spectral
analysis will be and the more questionable the accuracy of the
metabolite concentration measurements is.
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Problems with relaxation rate measurements:
Methods to measure the relaxation times Ti and T2 ---
The longitudinal relaxation time (TI) describes how fast the
disturbed magnetization will return to thermal equilibrium. The T,
value is traditionally measured by a series of inversion recovery
experiments stepping through variable inversion recovery waiting
times (TI). The spin-spin relaxation time (T 2) is a function of echo
time TE and can be measured by series of spin-echo experiments
stepping through several TE values. Equations (2-7) and (2-8)
describe the mathematical expressions of these measurements:
TR TR TESI = Mo(1 -2exp(- ))(1 - exp(- ) )exp(- ) (2-7)
T1 TI T2
= (TE2 - TE2) (2-8)
In(SI1 - SI2)
However, there are a number of possible problems involved in the
relaxation time measurements:
Partial volume averages and heterogeneous environments:
Due to the limitation of spatial resolution, for both in plane and
through plane resolutions, the spectral voxel may cover
heterogeneous structures and may be contaminated by structures
adjacent to but outside the voxel. Different types of tissues (e.g.,
gray matter(GM), white matter(WM), and cerebrospinal fluid (CSF))
have different metabolite compositions and the same metabolites in
different types of tissues may possess different relaxation times (e.g.,
brain tissue H2 0 with T2 = 70ms and CSF with T2 = 2s). Kreis et. al.
[1l] has showed a large scatter in the in vivo relaxation time
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measurements partially due to the contamination of CSF, arterial and
venous blood, as well as other small sources. For a spectral voxel
which contains or is contaminated by multiple tissue structures, the
spectral signal will be just the sum of signals from all of the
structures:
SIA = ISIAn
n
TR TE
= f An(l- exp(- ) )exp(- ) (2-9)
n T1An T2An
where,
SIA = signal intensity of metabolite A,
SIAn = signal intensity of metabolite A from structure n,
fAn = fraction of total proton intensity contributed from structure n,
T1An, T2An = T 1 and T 2 of metabolite A from structure n.
As one can expect, the signal intensity will no longer follow a simple
mono-exponential decay and the T, and T2 relaxation time
measurements will be unreliable.
Spectral overlap and J-coupling effects:
As mentioned earlier in this chapter, the conditions to resolve two
spectral peaks are determined by their chemical shifts and line
widths. Some of the cerebral metabolites have very close chemical
shifts and it becomes difficult resolve them from each other. This
situation is especially severe at lower field strengths like 1.5T. For
example, the spectral peak of the methyl group of NAA (2.023 ppm)
overlaps with the peaks of GABA (1.91 ppm), NAAG (2.05 ppm), and
glutamate (2.06 ppm). Other than the simple singlet spectral
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overlaps, some of the overlapping peaks are J-coupled and their
spectral phases are modulated by the echo time TE. This kind of
complexity makes the spectral quantification difficult. Considering
both the spectral overlap and the J-coupling effects, equation (2-9)
can be rewritten as:
SI = SIn
TR TE
= Mon( 1 - exp(- ) )exp(- )TE Jn
n Tln T2n
(2-10)
where,
SIn= signal intensity from metabolite
M on = proton density of metabolite N
T1 n , T2n = TI and T2 of metabolite N,
J = J-coupling effect
=1 for singlet peak
= 1/2 cos(2t J/2 TE)
= 1/4 cos(2x J TE)
= 1/2
= others
for each doublet peak
for the 2 side peaks of triplet
for the middle peak of triplet
for higher multiplicity
Table 2-2 is a list of some of the spectral groups with possible
spectral overlap.
43
Metabolite ppm multiplicity Mo (mM)
NAA (CH3) 2.023 s 8
NAAG 2.05 s 0.79
Group I Glutamine (P-CH 2) 2.1 m 6.8
Glutamate (P -CH2) 2.14 m 6.8
GABA (3 -CH2) 1.91 qu 3.61
Group II PCr/Cr(CH3) 3.05 s 7.6
GABA (y-CH2) 3.02 t 3.61
Choline (CH3) 3.25 s 1.6
Group II myo-Inositol 3.2 dd 5
Taurine 2.3 t 2.3
Table 2-2. List of major spectral overlap groups in 'H-MRS.
Here in this chapter, we will demonstrate how the spectral overlap
and the J-multiplicity may degrade the spectral quality and thus
reduce the accuracy in T 2 relaxation time measurements.
Furthermore, we will describe how the errors in relaxation time
measurements lead to errors in absolute metabolite concentration
estimates.
Methods:
Computer Simulation
All of the computer simulations were performed with MATLAB (the
Math Works, Inc.) programs.
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Spectral simulation :
Human cerebral 1H MR spectra were computer simulated with
preassigned values of molar concentrations and relaxation rates (Ri
and R2) with most of the major cerebral metabolites detectable from
'H MRS as indicated in table 2-1. The absolute metabolite amounts
were set to physiological levels [13]. Chemical shifts (ppm),
multiplicities, and coupling constants of those spectral peaks were
obtained from the literature [14]. The MATLAB program assumes a
spin-echo experiment is performed and allows one to specify the
magnetic field strength, spectral resolution (via spectral sweep and
number of data points), and echo time (TE). The field inhomogeneity
is reflected as an extra factor in R2* (Hz) as expressed in equation (2-
6). This program assumes perfect water and lipid suppression (zero
signal contamination from water or lipid) and weak J-coupling only.
Macromolecular contamination was not included in this simulation
[15,16]. For the spectral peaks with higher order J coupling, this
MATLAB program simplified the complex spectral formation by
using double doublet peaks (i.e., split a single spectral peak to be
doublet peaks with J1 spectral distance (ppm); then split each peak
to be doublet again by J2 spectral distance (ppm)). Table 2-3
illustrates the spectral elements used in this simulation. Amplitude
spectra of both multi-metabolite (sum of all of the metabolite
spectral lines) and individual metabolite spectra were plotted
separately and coded with different colors.
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metabolite Mo (mM) ppm multiplicit J # of rotons
2.01 1 N/A 3
NAA 11 2.7 c 3.7, 15.9 1
2.52 c 9.8, 15.9 1
4.4 c 3.9, 9.8 1
creatine 7.6 3.05 1 N/A 2
choline 1.6 3.25 1 N/A 9
taurine 2.3 3.44 3 6.7 2
3.27 3 6.7 2
3.55 c 2.7, 9.9 2
myo-inositol 5 3.65 2 9.8 2
3.77 2 9.8 1
3.28 3 9.2 1
3.80 a- CH, 3 7.3 1
glutamate 6.8 2.10 P- CH2  c 7.3, 7.3 1
2.35 y-CH C 7.3, 7.3 1
3.78 a- CH2  t 7.3 1
glutamine 6.8 2.14 P- CH2  c 7.3, 7.3 1
2.46 y-CH c 3.6, 7.3 1
lactate 0.7 4.12 4 7.3 1
1.33 2 7.3 3
Table 2-3 Spectral elements used in Lorentzian line simulation.
T2 measurement errors:
For a simple singlet spectral peak without any overlapping peaks, the
signal intensities from spin-echo experiments should follow mono-
exponential decays as a function of echo time (TE) (equation (2-1)).
However, due to the spectral overlap and J-coupling effects, the total
signal intensity is not only likely to be a multi-exponential decay but
also to oscillate in a sinusoidal-like form along TE axis [17]. We used
MATLAB to simulate this multi-exponential decay and sinusoidal
oscillation phenomenon. We paid particular attention to three
prominent metabolite spectral groups in the typical 1H MR cerebral
spectrum: NAA(methyl group, 2.023 ppm), creatine(3.05 ppm), and
choline(3.25 ppm). Metabolites with chemical shifts less than 0.1
ppm away from any of the 3 major spectral locations were classified
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to be the same spectral group as the major metabolite (Table 2-2).
The MATLAB programs ignore any chemical shift differences
between the major and the minor metabolites (e.g. major = NAA and
minors = NAAG, GABA, Glx) in the same spectral group and the total
spectral signal intensity of the spectral group was calculated simply
by summing up all of the metabolite signals in the same spectral
group. The pure T2 decay curves (as a function of TE) of the major
metabolite as well as the composite T2 decay curve from all of the
metabolites are synthesized separately according to equation (2-10)
The T2 decay curves were then presented in a semi-logarithm
fashion (log(SI) versus TE) and a least-squares fitting program was
applied to the composite data set to estimate the "measured T2"
value of the major metabolite. The T2 error was then computed as a
percent deviation of the "measured T 2" from the "pure T," of the
major metabolite.
Absolute concentration measurement errors:
The absolute concentration of the cerebral metabolite can be
estimated according to equation (2-5). However, this measurement
involves a lot of other measurements such as T2 measurements of the
internal standard metabolite and the one to be quantified.
Statistically, the propagation of errors of the measured absolute
concentration Ub can be expressed as equation (2-11):
2 2 2[A] Mo GMoG[A] M + (2-11)
[A] MO s MO)A
where,
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GMoOJ2QGSI)2Q +TE 2 GT2 2TR U2 (2-12)
-o SI -2 -2 1 1- exp( ) ( TjMO S ýT2) T2 , I j
We, again, utilized MATLAB to simulate the error properties of this
absolute concentration estimation. In this case, water was used as
the standard metabolite to measure the NAA concentration. The
percent error of the NAA concentration was estimated according to
equation (2-11) with the four variables : errors of T, of water (Gtlw),
Tz of water ('t2w), Tl of NAA (GOtlNAA), T2 of NAA (G't2NAA). The
simulation fixed 3 of those 4 variables and varied the 4th variable in
the range of error between -100% and 100% with an increment step
of 10% error in the relaxation time. In this fashion, one is able to
study the property of the concentration error caused by this
particular relaxation time error.
Phantom and in vivo spectra
In order to verify the computer simulation results, especially for the
Tz measurement errors, phantom spectra as well as in vivo human
cerebral spectra were obtained with the same parameter settings as
used in computer simulations. All of the spectroscopy experiments
were conducted on a 1.5 T imager (Signa, GE). In order to get single
voxel spectra, a PRESS sequence was used to acquire data instead of
using spin-echo sequence as was used in computer simulation. Two
second repetition times (TR) were used in both human and phantom
studies and the echo tinie was stepped from 51 to 304 ms with
approximately 10 to 17 ms increments for total of 18 points. Shorter
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echo times ( TE <40 ms) were desirable but were not possible using
the GE PRESS sequence at the time. For the phantom study, a bottle
of agar gel mixed with NAA (10mM ), glutamate (9.7mM), glutamine
(3.7mM), and GABA (3.29 mM) was used to simulate the cerebral
metabolite contents. For the in vivo study, spectra were taken from
occipital cortex of healthy human volunteers.
Results and Discussions:
Spectral simulation:
The spectra were computer simulated specifically for the magnetic
field strengths of 1.5, 4.7, and 9.4T (the major magnets used at NMR
center, Massachusetts General Hospital, MA). To simplify the
complicated metabolite compositions, we assumed the T2 of NAA to
be 450 ms and the other metabolites to be 400 ms. The spectra were
synthesized either with short echo times (TE = 68 ms), intermediate
echo times (TE = 136ms) or long echo times (TE= 272ms). To set the
echo times to be multiple of 68 ms is essential to refocus those
magnetizations with J-modulation of 7.3 Hz. Figure 2-1 shows typical
spectra with reasonable magnetic field homogeneity (8R2 = 10 Hz)
under the three main magnetic field settings. Figure 2-2 shows
spectra with relatively bad shims (6R2 = 50 Hz). In each diagram,
the top box shows the mixing spectrum (the summation of the
individual spectra) with different color codes to highlight the
'presumable'major metabolite peaks ( NAA, Cr, and Cho) and the
bottom box shows the 'real' spectra from the individual metabolites.
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a.) Spectra with reasonable shim (6R2 =10 Hz) -- For field
inhomogeneities less than 8R2 of 10 Hz, the NAA methyl group at
2.023 ppm is not severely contaminated by other metabolites at
higher field strengths (Bo >= 4.7 T). However, at the low field
strengths (Bo =1.5 T), this peak is heavily contaminated by
glutamate, glutamine, NAAG, and GABA. At an echo time of 68 ms,
those doublet and quadruplet peaks with J equal to 7.3 Hz, such as
the quadruplet peaks of GABA at 1.91 ppm, will be out of phase and
contribute no signal to the "observed NAA" peak. In other words,
the NAA peak at 2.023 ppm is less contaminated by GABA at echo
time of 68ms than echo times of 136 or 272ms. On the other hand,
the doublet peaks of lactate at 1.33 ppm will be out of phase, too,
and it would be a big loss to underestimate this important cerebral
metabolite, which is of particular interest to cerebral physiology and
studies of energy impairment. Since the linewidth is so narrow with
8R2 =10 Hz and the spectral amplitude of the pure NAA peak is
usually much higher than the amplitudes of the overlapped
metabolites, the pure NAA peak can thus be fit relatively accurately
when one has a good baseline. However, for longer echo times such
as 136 ms and 272 ms, this NAA peak is heavily distorted by
glutamate, glutamine, and GABA. Under this condition, it becomes
difficult to fit the pure NAA peak because the non-negligible
amounts of glutamate, glutamine and GABA will modulate the
baseline level and spectral phase. The same chemical contamination
phenomena were observed for the creatine and choline peaks in low
field cases. Comparing those spectra simulated at 1.5T with the 3
echo time settings, it is clear that the lower the echo time is, the
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more spectral information is presented in the spectra. This is
because SNR is degraded at the longer echo times, especially for
those metabolites with low proton densities and high relaxation rates
(R2). Nevertheless, an echo time of 68 ms is generally not desirable
because the loss of lactate information and the possible
contamination of macromolecules. For other shorter echo times that
people routinely use such as TE = 20ms, our computer simulation did
not show great difference in the degree of spctral overlap in NAA, Cr,
and Cho as in TE = 272ms cases. However, this simulation with short
echo time may not reflect the real spectra because our simulation did
not take the consideration of macromolecules which have relatively
short T 2 relaxation times. Also, lipid which is at around 1.33ppm is
generally overlapped with lactate signal. Since lipid has relatively
short T 2 relaxation time (= 50ms), the lipid contamination may only
be problematic in shorter echo time instead of longer echo time
experiments.
b.) Spectra with bad shim (8R2 > 50Hz)-- The situation for the
spectra with bad shim is much worse. For a field inhomogeneity of
8R2 = 50 Hz, it is almost impossible to separate the major metabolite
peaks (NAA, Cr, Cho) from the minor metabolites (GABA, Glutamate,
Glutamine, taurine,etc), especially at low magnetic fields. As
indicated in figure 2-2a, the fusion of the minor metabolites disturbs
the baseline level and makes the spectral phase adjustment difficult.
Moreover, it becomes hard to determine the real spectral linewidth.
Taking the methyl NAA peak as an example, it is difficult to
determine how wide the Lorentzian line should be to match the true
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NAA peak in the top spectrum of figure 2-2a. Even for higher
magnetic field strengths, there is still certain degree of chemical shift
overlap. For example, it is tricky to isolate out the pure creatine
signal from the baseline due to the overlap of other chemicals. This
is a particularly important issue because creatine is often used as the
internal metabolite standard to measure the absolute or relative
concentrations of the other cerebral metabolites.
T, measurement errors:
Figure 2-3 shows the semi-log plots of the synthesized 'NAA' signal
intensity versus echo time (TE). The contents of this 'NAA' group
include NAA with minor contributions from NAAG, glutamate,
glutamine, and GABA. The solid red lines represent the "pure" NAA
signal and the other color coded lines represent the "observed"NAA
signals which are contaminated by the overlapping metabolites with
different T 2 values. In this simulation, the T2 value of one of the
minor metabolites is fixed (e.g., glutamate = 300ms in figure 2-3a)
while the T2s of the other 2 minor metabolites (e.g., GABA and NAAG)
were stepped between 100 to 500 ms in 100ms increments. The
lines are coded to different saturation levels to represent the specific
T2 values over the T2 span. The darker the line is, the smaller the T2
value is. Because all of the minor metabolites in this 'NAA' group are
J-coupled, each single minor metabolite will have its signal decay in a
sinusoidal oscillation. Depending upon the ratio of the preassigned
molar concentrations among these minor metabolites, the summed
signal will cross the 'pure' NAA line at different TE points. In other
words, not knowing the relative amount of those other metabolites, it
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is impossible to find the optimized TE values to ensure that the
'observed' NAA signal deviates the least from the 'pure' NAAdecay
line. Similar phenomena were found for 'creatine' and 'choline' as
shown in figure 2-4. If we try to fit this oscillating decay curve to
get the "measured T 2" value, T 2 errors can be expected. The
estimated T2 error of NAA can be as big as 50% with reasonable T2
settings of the minor metabolites ( = 360 ms).
Our experiments of both phantoms and in vivo occipital cortex
spectra showed similar oscillatory phenomena. The phantom and in
vivo spectra turned out to match the computer synthesized spectra
quite well even though the simulation assumed weak J-coupling only
and a single spin-echo rather than PRESS (which has two 180 degree
pulses). Figure 2-5 shows a stack plot of phantom spectra and
figure 2-6 shows a stack plot of in vivo spectra. In the human
spectra, several subsets from the 18 TE data sets were used to
estimate the T2 value of NAA. The results ranged between 400 ms to
1200 ms depending upon which TE points were included in the
subsets. This confirms the observation from the computer simulation
and leaves the accuracy of cerebral metabolite T z measurements to
be suspect.
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Figure 2-3 Signal intensity as a function of TE at around 2.023 ppm
which is dominated by NAA. The pure signal intensity of NAA is
presented as thick solid red line. The color curves represented the
"measured" signal intensity with contamination of other overlapping
compounds with different T2 value combination. (A) The "observed"
signal of NAA with fixed T2 of glutamate. (B) The "observed" signal
of NAA with fixed T2 of NAAG.
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Figure 2-4 Signal intensity as a function of TE at around 3.03 ppm (A)
and 3.23 ppm (B) which are dominated by creatine and choline,
respectively. The pure signals for Cr and Cho are presented as thick
solid red lines. The color curves represented the "measured" signal
intensity with contamination of other overlapping compounds.
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Figure 2-5: phantom spectra
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Figure 2-6: occipital cortex spectra.
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Absolute concentration measurement errors:
Correlations between errors of the NAA concentration and relaxation
time measurements were performed. Water was assumed to be the
internal standard due to its relative invariance in molar
concentration in the brain. Out of the 4 relaxation error variables
([Etlw, Et2w, EtlNAA, Et2NAA] = [(tlw/Tlw, Ot2w/T2w, OtlNAA/T1NAA,
(Gt2NAA/T2NAA] ), we assumed 3 of them with 10% errors from the
principle values of relaxation times while the 4th variable was
stepped between 0 and 100% error to build the error correlation
curves. Figure 2-7 shows the simulation results. For a given
repetition time (TR) of 2 s, which is the TR used for the phantom and
in vivo studies, the water magnetizations will have enough time to be
close to fully recovered between excitations (TI water = 950 ms) and
thus the TI errors of water won't play an important role in the
concentration error of NAA (figure 2-7 a). On the other hand, since
the T, of NAA (= 1600 ms) is much longer, a two sec TR is not long
enough to allow the full recovery of the magnetization of NAA and
thus the T, error of NAA will not be negligible in the concentration
estimate (figure 2-7 b). Figure 2-8 shows how TR effects NAA
concentration estimate-the curves are steeper as TR goes shorter.
For a TR value bigger than 2s, the concentration error induced by T,
NAA will become tolerable (the amount of concentration error caused
by every 1% increase in NAA T, error is smaller than 0.2%). Kreis et.
al. [10] has reported that the longitudinal relaxation times (TI) of the
major peaks in an in vivo proton spectrum are close to each other
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and the relative peak intensities are less sensitive to the repetition
times (TR). In other words, if an appropriate saturation factor is
used for corrections, the absolute concentration is less dependent on
repetition times greater than about 1.5 second. The concentration
error caused by T2 errors of water or NAA, in the other hand, are not
negligible no matter what TR and TE values have been chosen (figure
2-7 c,d). The error could be as high as over 100% in NAA
concentration estimates. Therefore, the accuracy of T2 measurements
are much more important than the accuracy of T, measurements.
This is bad because the T2s are harder to measure than the Tis due to
J-modulation. For all of the cases we represent in figure 2-7, the
error curves from shorter echo times are in the lower part of the plot
than those with higher echo times. However, this does not imply that
the smaller the echo time is, the more accurate the concentration
estimate is. The spectra with shorter echo times are frequently
further contaminated by macromolecules[15], which will complicate
the spectral composition and decrease the accuracy of T2
measurements, and will move the errors toward the lateral upper
corners along the concentration- T2 error curves( figure 2-7 c and d).
The concentration error is especially notable in the T2 water case due
to the steeper slope as shown in figure 2-7c. Because the slope of
this error curve is so steep, a small increase in the water T2 error
might triple the NAA concentration error.
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TR settings. (A) TE = 68 ms, (B), TE = 272 ms.
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Conclusions:
By using computer simulations, we have synthesized 1H spectra
similar to real spectra from 1.5T and 4.7T (figure 2-9). This
emphasizes the importance of the accuracy of relaxation time
measurements in the metabolite concentration estimates. It also
points out how problematic it is to obtain accurate "absolute"
concentrations. Unless one knows: a) the behavior of the strongly
coupled metabolites under the influence of the particular pulse
sequence used, b) all the chemicals contributing to the overlap, and
c) the macromolecular concentrations and chemical shifts,
measurement of absolute concentration will remain elusive. An
alternative solution is to use signal from proton density weighted
experiments as an internal standard to obtain a metabolite index
(Mindex = SImetabolite /SIproton density). This metabolite index method
will minimize the concentration error from the relaxation time
measurements and allow relatively accurate inter-subject
comparisons[18]. Although the absolute metabolite concentration
measurements has been a great desire and the 'holy grail' of 1H MRS
over decades, relative concentration measurements may prove to be
more useful and reasonable for quantitative analysis.
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(A) 1.5T
3.00 2.00 1.00 0.00 -1.00
mm~ XI
(B) 4.7T
PPM
Figure 2-9. In vivo spectra from 1.5T (A) and 4.7T(B). (A) is from the occipital
cortex of a HD patient and (B) is from the striatum of a rat with intrastriatal
injection of MPP+.
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Chapter 3 1H Magnetic Resonance Spectroscopic
Studies in Parkinson's Disease Patients
Introduction and backg-round
Parkinson's disease (PD) is one of the most common neurological
diseases in North America with an average onset age of 58 years.
Statistically, the annual incidence rate of PD is 20.5/100,000
population and the prevalence rate is 300/100,000 population in
North America as in 1991 [1]. The symptoms of PD usually starts
asymmetrically on one side of the body. Although James Parkinson
[2]described the motor disorders associated with PD in 1817 and
since then the PD symptoms have been well documented, the
etiology of this disease, however, is still unclear. One popular
hypothesis of the etiology of PD was inspired by human evidence:
seven street drug abusers received an intravenous injection of I -
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methyl-4-phenyl- 1,2,3,6-tetra-hydropyridine (MPTP) and developed
symptoms resembling idiopathic Parkinson's disease[3]. The
metabolite of MPTP, 1-methyl-4-phenylpyridinium ion (MPP+), is
taken up by dopaminergic reuptake system and is transported to the
substantia nigra pars compacta (SNc) where it accumulates in the
matrix of mitochondria. MPP + is a potent inhibitor of complex I in
the electron transport chain. The accumulation of MPP ÷ in the
mitochondrial matrix may lead to a reduction in ATP production [4]
which may subsequently cause the death of the SNc neurons.
Several biochemical observations have shown a 30%-35% reduction
in complex I activity in post-mortem substantia nigra[5,6,7] in PD
patients but with no abnormal enzymatic activity for complex III
and IV in immunohistochemical staining [3,8]. In contrast to this
finding, multiple system atrophy (MSA), a similar neurological
disorder associated with dopaminergic cell loss, appeared to have
normal enzymatic activity in complex I [9]. The etiology of PD thus
has been hypothesized to have a special association with a
dysfunction of energy respiration. Since the cessation of oxidative
phosphorylation may force pyruvate, the final product of glycolysis
and the key element to enter TCA cycle, to be shunted to lactic acid
instead of acetyl-CoA [10], a dysfunction in the enzymatic activity of
complex I may lead to extra accumulation of lactic acid.
Localized 'H MR spectroscopy has recently become a powerful
technique to investigate cerebral metabolites. N-acetyl-aspartate
(NAA), which is a neuron-specific brain metabolite [11,12,13,14], has
been used as neuronal marker in 'H MRS and has been widely used
to verify the viability of the cerebral neurons. Detection of lactic
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acid has been studied in 'H MRS for many years [15,16] and has been
used as an energy impairment marker to test the mitochondrial
function [17,18]. Other 'H MRS detectable metabolites have been
proposed as useful markers for other cerebral conditions. Creatine
can serve as an internal standard to estimate the relative ratio of all
other cerebral metabolites due to its relative invariance in
concentration in different disease states [see chapter 2]. The 'H-MRS
technique has been successfully applied to examine the clinical
aspects and the possible etiologies of several neurological diseases.
Huntington's disease (HD) is a genetic inherited movement disorder
which has been hypothesized as a neurological disorder associated
with energy impairment (complex II ~ IV) in the basal ganglia.
Jenkins et. al. [17] applied localized 'H-MRS to HD patients and
observed significant lactate elevation in the striatum and occipital
cortex. The elevated lactate level in the HD brain suggests an
abnormality in oxidative phosphorylation and 'H MRS has shown a
promising ability to detect the possible energy impairment in human
brain. We thus proposed use of 'H MRS to investigate the energy
metabolite condition in PD brains. Although one would like to
examine metabolites in the substantia nigra (SNc) where
histochemical studies in postmortem PD brains have found abnormal
dopaminergic neuronal loss [19,20,21,22], it is difficult to acquire
spectra with reasonable quality from this area because of the low
signal to noise ratio (due to the very small structure size) and the
possible signal distortion caused by magnetic susceptibility
perturbations due to the high iron content in this organ. Since the
SNc is the primary dopaminergic source for the central nervous
system, degeneration of the SNc cells may lead to insufficient
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dopamine innervation in the downstream structures of the meso-
telencephalic dopaminergic pathway, such as striatum and frontal
cortex. The deficit in the dopamine innervation of these downstream
cerebral structures is the cause of the motor and/or mental disorder
in Parkinson's disease. Although there is no evidence in PD patients
of massive neuronal loss other than the dopaminergic terminals in
the neostriatum, striatal tissue does show decreased staining of
complex I proteins in a Western blot and decreased complex III
activity [23,24]. Genetic studies have found mutations in
mitochondrial DNA that may be associated with PD and the basal
ganglia may be vulnerable to defects in oxidative phosphorylation
[25,26]. We hence propose to examine the energy respiration status
of basal ganglia instead of the tiny SNc to verify the energy
impairment hypothesis. We propose to use localized in vivo 'H MR
spectroscopy to examine the striatal metabolites in PD brains,
particularly the resonances of the methyl group of NAA at 2.023
ppm and lactate at 1.33 ppm. This 'H-MRS metabolite study should
provide further information to help understand the biochemical
etiology of Parkinson's disease.
Methods
Idiopathic Parkinson's disease patients and age-matched normal
volunteers were included in this study. The range of the disease
severity of this patient group is listed in Table 3-1 . Most of the
normal volunteers were the spouses or close relatives of the PD
patients. MR studies were performed on a 1.5T whole body magnet
(Signa, General Electric Co.) with a quadrature head coil as RF
transmitter and receiver. The subjects' heads were packed tightly
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inside the head coil to prevent head motion during the scan as the
position and the grey/white-matter ratio inside the spectral voxel
may change critically with only a slight shift in position. Coronal
images with good grey/white matter contrast from a fast spin-echo
(TR/TE = 287 / 3.4 ms, 16 echo trains) were used to locate the
spectral voxel in the striatal areas. A point resolved spectroscopy
sequence (PRESS) with water suppression was used to acquire the
striatal spectra (TR/TE = 2 s/272 ms, number of averages > 400).
Spectra of the PD patients were either taken unilaterally (n = 23) or
from both of the striata(n=20). Twelve out of 19 normal controls
also had the spectra obtained from both striata rather than a single
striatum. Since the PRESS sequence can only excite a rectangular
voxel, the spectral voxel was positioned to cover most of the caudate
nucleus, putaman, globus pallidus. However, it is almost impossible
to exclude part of the ventricle and white matter (internal capsule)
from this spectral voxel and thus a certain degree of signal
contamination from the heterogeneous structures is impossible to
avoid. The spectral compositions for white matter and grey matter
are different. Therefore, one has to pay particular attention to the
amount of spectral contamination from white matter. A small voxel
size (= 4.0+0.6 cc) thus becomes critical and necessary to estimate the
striatal metabolite levels accurately to avoid the possible spectral
distortion by the white matter. In contrast, cerebrospinal fluid (CSF)
creates few problems and can plausibly be ignored in the striatal
spectra. Previous studies [27] have shown that CSF does not
contribute much of spectral signals in 'H MRS due to the pulsation of
the CSF. The striatal spectra acquired from the imager were then
transferred to a SUN UNIX workstation and were analyzed by using
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commercial spectroscopy analysis software NMR1 (New Methods
Research Inc., Syracuse, NY). Data were processed using zero fill,
baseline correction, exponential filtering and Fourier transformation.
Each spectral peak was then fit to a Lorentzian line and the integral
value of the peak was used as the index of the striatal metabolite
level.
Table 3-1 Clinical characteristics of the PDpatients participating the
'H MRS studies. Total number of PD patients is 22.
Results
Among the spectra of 23 PD patients and 20 age-matched normal
volunteers, we found that the metabolite ratio of creatine (3.02 ppm)
to NAA (2.023 ppm) was quite consistent (42±0.5% of NAA, 2 tailed T
test: P > 0.95). Since the spectral peak at around 2.02 ppm
(dominated by the methyl group of NAA) has higher signal intensity
and less baseline distortion than the spectral signal at around
3.02ppm (dominated by creatine), we chose to use NAA instead of
creatine as the internal standard to yield higher precision in the
relative metabolite measurements. The use of NAA as the internal
standard is legitimate since there is no observable striatal or global
brain atrophy in the PD patients. A two tailed student t statistic test
was used to examine the significance of differences in the
metabolites between the PD and the control groups.
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Average result from the individual spectra-
When the lactate to NAA ratios from individual spectra were
averaged together (Table 3-2), the average lactate level was
significantly elevated in the PD group compared to the control group
(59% higher; p value < 0.0004). This measurement treated each single
spectrum as an individual entity regardless of which hemisphere the
spectrum came from (the first affected striatum or not) and whether
or not more than one spectrum was taken from the subjects. No
other 'H-MRS detectable metabolites were found with a significant
difference in the PD group compared to the control group. Figure 3-1
shows pairs of spectra from PD patients and normal controls.
PD Control
# of subjects 2 3 20 P value
# of spectra 4 3 3 0
age (yrs) 62 ± 10 58 ± 12 > 0.3
Lac/NAA (%) 12.33 ± 0.59 7.77 ± 0.34 < 0.004
Cr/NAA (%) 42.86 + 0.46 42.92 ± 0.66 > 0.95
Cho/NAA (%) 51.95 ± 1.03 47.86 ± 0.99 > 0.15
Glx/NAA (%) 13.58 ± 0.69 15.45 ± 0.98 > 0.4
Asp/NAA(%) 10.16 ± 0.50 10.31 ± 0.78 > 0.9
Table 3-2 Cerebral metabolite levels measured from PD patients and
age-matched normal control volunteers. Lac: lactate, Cr: Creatine, Cho:
choline, Glx: glutamate and glutamine, Asp: aspartate. (metabolite
ratio: mean ± standard error; age: mean ± standard deviation)
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Cho NAA
Lac (A)
3.00 2,00 1.00 0.00 -1.00
PPM
3.00 2.00 1.00 0,00 -1.00
PPM
3.00 2.00 1.00 0.00 -1.00
PPM
3.00 2.00 1.00 0.00 -1.00
PPM
3.00 2.00 1.00 0.00 -1.00
PPM
Figure 3-1. Striatal spectra from PD patients (A) (B) (C) and age matched normal controls (D) (E) (F).
(C)
3.00 2.00 1.00 0.00 -1.00
PPM
Asymmetric of the lactate levels in the two striata of the
subject-
Although the averaged data showed significant differences in the
lactate to NAA ratio between the PD and control groups, the
distribution of the individual ratios, however, fell into 2 categories -
high versus low lactate groups(Figure 3-2). If a Lactate/NAA ratio of
10% (one standard deviation above the mean of the lactate level in
the normal control group) is taken as a cutoff between low and high
values, 21 out 41 PD spectra belong to the high lactate level group
while only 5 out of 29 normal control spectra are in this high lactate
group. The lactate levels do not correlate with age, disease severity,
DOPA dose administrated, nor the duration of PD (Table 3-3). Upon
closer examination of the double spectra taken from the same
subjects (20 out of 23 PD patients and 9 out of 20 normal controls),
we found significantly asymmetric lactate levels in the two striata
for both PD and control groups. Figure 3-3 shows 2 sets of the
asymmetric spectra from the PD patients and Table 3-4 shows the
statistical results of the double spectra sorted according to 'big'
versus 'small' lac/NAA sides of the same subject. Figure 3-4 show
the statistical results as a bar graph. Only the 'Big' side showed a
significant elevation in lactate ( p <0.045). Interestingly, the "big"
side seems to be mainly the left striatum (8 out 9 in control group
and 17 out of 18 in PD patients).
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Figure 3-2 Distribution of the individual lactate to NAA ratios in the
42 PD and 33 control spectra from 24 PD patients and 22 normal
control subjects.
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(A) Patinet I: Left (B) Patient I: Right
3.00 2.00 1.00 0.00 -1.00
PPM
3.00 2.00 1.00 0.00 -1.00
PPM
(C) Patient II : Left (D) Patient II: Right
3.00 2.00 1.00 0.00 -1.00
PPM
3.00 2.00 1.00 0.00 -1.00
PPM
Figure 3-3. Asymmetric lactate level in the striatal spectra.
(A) and (B) are from PD patient I and (C) and (D) are from PD
patient II. Note the left striatum has higher lactate than the
right side.
NAA
Lac
Lac
Lactate/NAA (%) High (>10%) Low (<10%)
age (yrs) 60+10 58+12Ns
Duration of PD (yrs) 7.9±1.2 8.2±0.9 NS
DOPA dose (mg/day) 510+65 500±89 NS
Hoehn-Yahr stage 1.9±0.2 1.8±0.1 NS
Table 3-3 Correlations of the PD lactate to NAA ratios
parameters. NS: not significant (unpaired
with clinical
t test, 2-tailed)
Lactate/NAA (%) P age
small side big side (small v.s. big)
PD
8.17±0.50 17.85±1.17 < 0.001 61±10
n=20
Control
6.11±0.29 10.85±0.85 < 0.02 56+5
n=9
P (PD vs Control) > 0.17 < 0.05 > 0.4
Table 3-4 Metabolite levels from both striata of the same subject.
When the metabolite levels were grouped as to small versus big
lactate levels (relative to NAA), both the PD and control groups
showed asymmetric lactate amounts in the striata. The 'small' group
showed no significant difference between PD and control groups.
However, the 'big' group showed significant elevation of lactate in the
PD group.
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Figure 3-4 Lactate/NAA ratio comparison when the spectra from
both striata are broken into small versus big lactate side. The lactate
level is significantly higher on the 'Big' side in the PD but not the
control group (*p < 0.045).
Aspartate Elevation
Although there was no other 'H-MRS detectable cerebral metabolite
beside lactate showing a significant change in the PD group (Table 3 -
2), some of the PD spectra however showed some suspicious
modulation at around 2.8 ppm. This modulation may result from
elevated aspartate. Figure 3-5 shows some of these spectra. For
those spectra with narrow linewidths, a peak could be roughly
distinguished. However, for most of the cases, the linewidths were
not narrow enough to resolve the 2.8 ppm peak from the creatine
peak (3.0 ppm) resulting in an asymmetric shoulder on the creatine
peak. This adds to the difficulty of accurate quantification of both
the creatine peak and the aspartate peak. This aspartate peak,
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however, could potentially be better resolved from the creatine peak
and hence quantified more accurately at higher magnetic fields such
as 3T or 4T. The finding of this suspicious aspartate peak reveals
that PD may involve more complicated neurological modulations
which may provide valuable information worth pursuing to more
precisely establish the etiology of PD and also to verify more
completely the pathological changes in PD.
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(A)
3.00 2.00 1.00 0.00 -1.00
PPM
(B)
3.00 2.00 1.00 0.00 -1.00
PPM
(C)
3.00 2.00 1.00 0.00
PPM
-1.00
Figure 3-5. A peak at around 2.8 ppm may
represent an elevation in aspartate [indicated
by arrows] . These 3 striatal spectra are from
3 PD patients(A,B,C).
Discussion
Morphology and SNR considerations:
Defects in mitochondrial phosphorylation have been reported in
various movement disorders, such as Huntington's disease (HD) and
Parkinson's disease (PD). In PD patients, deficiencies in complex I
have been found in platelets [28], skeletal muscle [29,30], and brain
[3 1,32]. Our 'H-MRS study has supported the hypothesis of a
possible mitochondrial respiration deficiency in striatum by showing
significant elevation of the striatal lactate level in PD patients.
However, Holshouser et. al. [33] did not find significant elevation in
the striatal lactate in their multicenter 'H-MRS studies on PD
patients. However, we believe we have reasonable criticism of their
results. The Holshouser et. al. multicenter studies claimed to use a
voxel size of 8 ml to cover the striatum with less than 10 to 20 %
non-gray matter contamination. Morphological study of brain
structures reveals that the total volume of a normal adult striatum
(whole brain) is about 17 ± 2.48 ml [34], or about 8 ml in one
hemisphere. However, the shape of the striatum is complicated and
extends over [3cm, 3cm, 3.5cm] in the [AP, ML, DV] directions [35].
In other words, the 7 to 10 ml of striatal volume is nonevenly
distributed over a big volume of approximately 30 ml. The cubic
voxel of 8 ml Holshouser et. al. reported to use in their 'H-MRS
studies thus can not possibly cover less than 10 to 20 % of white
matter. Our 'H-MRS study used much smaller voxel in size ( 4 ± 0.4
ml) to cover most of the body of caudate nucleus, putaman, and part
of globus pallidus only. This small voxel can still not avoid the
contamination of white matter such as internal capsule, by our
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estimation the contamination is about 30 %. The neuronal
physiological demand and consumption of energy is essentially
restricted to gray matter only and any elevation in lactate level is
expected be located in gray matter. With the consideration of voxel
contamination, the 'H-MRS detectable lactate amount is to be
reduced by the degree of the contamination of white matter, e.g., a
30% contamination of white matter in the spectral voxel may bring
the ratio Lactate to NAA of 20% (pure grey matter) down to 14%
(whole voxel). The other notable problem is the issue of signal to
noise ratio (SNR). In theory, any measurable quantity has to have
SNR bigger than 1. In most of the spectral analysis, only the SNR of
NAA has been estimated since NAA is in general the most prominent
component in the 'H-MR spectra. For a given SNR of NAA, there is a
minimum detectable lactate to NAA ratio which is:
Lactate 100(%) = (3-1)
NAA min SNRNAA
In other words, for spectrum with given SNR of NAA (SNRNAA), the
lactate to NAA ratio is only reliable when the value is bigger than the
values obtained from equation 3-1. Although Holshouser et. al. used
a lactate sensitive echo time (TE = 136ms) which should yield nice
negative doublet peaks of lactate at 1.33 ppm, the criteria they used
to screen the spectra were not strict enough to detect the minimum
lactate level smaller than 33% of NAA (one of the criteria for them to
screen the spectra is SNR >3). In our 'H-MRS study, we used much
stricter and flexible criteria to screen the spectral data for the lactate
level. Figure 3-6 shows a scatter plot of (Lactate/NAA) to SNRNAA with
the solid line indicating the theoretically minimum detectable
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(lactate/NAA) as a function of SNRNAA. This SNR-(Lac/NAA) line
separates the spectral data into 2 distributions: any data point
falling into the area to the right side of the solid line is reliable, while
any data point falling into the left side of this line is problematic. We
further classified the area to the left side of the theoretical line to 2
subsets with the SNRNAA of 12.5 as the boundary line (= 1 standard
deviation below the mean SNRNAA in normal control group)-the
vertical dashed line in Figure 3-6: area A for SNR > 12.5 and area B
for SNR < 12.5. A signal to noise ratio of NAA of 12.5 ( one standard
deviation above the mean of SNRNAA) will yield the theoretically
minimum detectable Lac/NAA of 8.5%. Therefore, it would be safe to
float those data points in area A (indicated as V in Figure 3-6) to the
values right below the SNR-Lac/NAA line (indicated as 0 in Figure 3 -
6). However, any data point in area B has too much uncertainty in
the lactate level and has to be dropped off from this study (indicated
as x in Figure 3-6). With the confidence of our spectral quality, we
can be sure now that our detection of the lactate elevation in the PD
group is reliable at least with respect to SNR.
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Figure 3-6 Distribution of Lactate to NAA ratio versus signal to noise
ratio of NAA. The solid line indicates the theoretically minimum
detectable Lactate to NAA ratio as a function of the SNR of NAA. Any
data point to the right of the solid line (area C) is reliable. The dashed
line indicates I standard deviation below the mean SNRNA in normal
control group. Any data point in area B will be discarded (with
symbol x) and any point in area A will be floated to the value right
below the theoretical line (float from symbol V to symbol 0).
Therapeutic Implication:
If the mitochondrial respiration deficiency hypothesis is true, the
finding of elevation in PD lactate level may provide some therapeutic
strategies to slow progression of PD, such as boosting the
mitochondrial function using metabolic cofactors. In Huntington's
disease, Koroshetz et al [36] has administrated several mitochondrial
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respiration boosters such as co-enzyme Q (QO1) to those HD patients
with elevated basal striatal/occipital lactate levels. The post-
medication 'H-MRS examinations in those HD patients showed
significant drop in the previously elevated lactate levels. Although
striatum may only be one of the downstream structures in the
neurodegenerative process in PD, an energy boost may help to
decrease the rate of degeneration in the striatum and thus stop the
worsen of the movement disorder which PD patients may suffer.
Asymmetric Lactate levels :
The asymmetric lactate data brings up some interesting questions
about how the elderly human brain functions. In most of the PD
patients, the high lactate side happened to be the left striatum.
Similar findings have been reported by Jenkins et. al. in 'H-MRS
studies of Huntington's disease (HD)[36], although the age
distribution in HD patients was much lower than the PD patients. A
hypothesis can be proposed that the left and right striata in the
human brain may possess different degrees of vulnerability when
the striata encounter certain energetic stress. In other words, the
vulnerability of the striatum may correlate with the working/firing
frequency that the striatum has performed over its life time. Since
most people are left hemisphere dominant and the left hemisphere
has long been hypothesized to govern the mental computation and
language. The left striatum thus has been hypothesized to have a
heavier working load than the right striatum. The higher neuronal
firing rate in the left striatum may lead to greater vulnerability with
energy stress or activation and this may be the cause of the
asymmetric lactate levels in the two striata.
91
Conclusions
The in vivo chemical/ metabolite study of the human brain using 'H -
MRS has provided valuable information to evaluate the neuronal
status in various neurological diseases. Here we used this technique
to explore the possibility that prolonged energy stress may lead to
mitochondrial impairment and cause dysfunction in the striata of the
PD patients. The finding from this 'H-MRS study may help provide
clues to the etiology of Parkinson's disease and may help
researchers to design more advanced and sophisticated experiments
for a better understanding of the normal striatal function as well as
the dysfunction in the PD patients. Such designs may include the
monitoring of the dynamics of the lactate levels or regional cerebral
blood flow (rCBF) and volume (rCBV) changes in the striatum during
physiological challenges such as the performance of certain motor
tasks. However, unlike in HD, PD may not represent a single disease
process and may be involved in multiple modulation of the
neurotransmission system as well. The results from our 'H-MRS
study provide information about possible energy defects in PD, but
many other hypotheses and techniques need to be studied before the
etiology of PD is understood.
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An Animal Model of Parkinson's Disease
using 6-hydroxydopamine Lesions in
Rats --- Anatomical and Metabolite
Magnetic Resonance Imaging Studies
Introduction and background
Dysfunction of the nigrostriatal dopaminergic system has been long
recognized to be involved in idiopathic Parkinson's disease.
Postmortem histological studies in PD brains have found significant
loss of the pigmented dopaminergic neurons in the substantia nigra
pars compacta (SNc) with little apparent atrophy in the striatum (str)
[1,2,3,4,5]. The SNc is the primary dopamine source of the
dopaminergic neurotransmission system. Dopamine is synthesized in
the pigmented dopaminergic cells in SNc and transported to the
striatum through the medial forebrain bundle (MFB), the
97
Chapter 4
nigrostriatal dopaminergic pathway [6,7]. Thus, anterograde
degeneration from the SNc to the neostriatum is a distinct possibility.
6-hydroxydopamine (6-OHDA), a well known dopaminergic
neurotoxin, has been widely used in animal models to mimic the
dopaminergic depletion of Parkinson's disease' [8,9]. Injection of 6-
OHDA into the medial forebrain bundle can selectively destroy the
dopaminergic neurons without interruption of many of the functions
of other neurotransmitters and thus is able to ablate the
dopaminergic innervation from the SNc to striatum [8]. When the 6 -
OHDA lesion is performed unilaterally, only the ipsilateral striatum
suffers the abnormality in dopaminergic stimulation while the
contralateral striatum remains intact and is essentially normal. This
unilateral abnormality makes it possible to inspect the survivability
of the dopaminergic terminals in the ipsilateral striatum by using
behavioral tests without sacrificing the animals (pharmacological
stimulation) and to have an internal comparison between the 2
striata (intact versus ipsilaterally lesioned striata) in the same rat as
well as make external comparisons among individual rats. The well
established behavioral test using pharmacological stimulation of
amphetamine (5 mg/kg, s.c.) provides a method to estimate the
degree of the dopaminergic loss quantitatively in the striatum
unilateral to the 6-OHDA lesioning (see appendix). The 6-OHDA
animal model provides the opportunity to investigate the connections
iSix-hydroxydopamine is an analogue of dopamine with high affinity for the catecholamine
uptake systems. It can be administered either via the cerebrospinal fluid or directly into
brain parenchyma and the neurotoxin will be transported into catecholaminergic neurons.
Pretreatment of animals with desipramine (DMI) blocks the uptake of 6-OHDA into
norepinephrine containing terminals and constrains the neurotoxin to the dopamine-
containing terminals [1,6,17,18,19].
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between : 1. the hypothesis that the neuronal loss in SNc is induced
by a possible energy impairment in the mitochondria [10,11,12,13],
and 2. the fact that the striatal dysfunction in PD is caused by the
insufficient dopaminergic supply from SNc [1,14,19]. We thus
propose using unilaterally 6-OHDA lesioned animals to investigate
the possible association between the dopaminergic innervation and
the global striatal physiology. In this chapter, we will to examine the
possible global physiological and neurological abnormalities in
striata, such as the changes in the macro cellular water properties
using T2 and diffusion weighted images, the major brain metabolite
levels using spectroscopic imaging (chemical shift images, CSI) of
NAA and lactate, and the hemodynamic properties (rCBF and rCBV)
by using bolus injection of Gd-DTPA [15,16]. In the next chapter, we
will propose to examine a possible abnormality in neuronal activity-
the coupling between the dopamine-receptor activity and the
regional hemodynamics in response to pharmacological stimulation.
Methods
Animals
Sprague-Dawley rats were used for all studies. Control animals were
studied as well as 6-OHDA lesioned ones. To make lesions in the
MFB, rats were first anesthetized with ketamine (50 mg/kg
ketamine, 5mg/kg xylazine, 2.5mg/kg acepromazine). Desipramine
(20 mg/kg, i.p.) was injected intraperineally (i.p.) 30 minutes prior to
the 6-OHDA infusion to restrict the effect of 6-OHDA to the
dopaminergic neurons[17,18,19, also see footnote i in page 98]. The
animals were then placed in a sterotaxic device and received
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unilateral injection of 6-OHDA into the medial forebrain bundle
(Coordinates: [AP, ML, DV] = [-4.5,+1.2,-7.6], 8 jtg/2gl, iced and
stabilized with ascorbic acid [6,17]). After the intracranial surgery,
animals were transferred back to the animal facility and allowed to
recover for at least 3 weeks" [20,21]. Behavior was assayed by
rotational testing to screen out those rats with less then 90%
dopaminergic neuronal loss in striatum [22]. For this, 5 mg/kg
amphetamine was given subcutaneously (s.c.) and the animal was
placed in a computerized rotameter (San Diego Instruments, CA) to
record the number of turns ipsilateral or contralateral to the lesioned
side for 90 minutes in 10 minute intervals (see appendix). The
criterion for inclusion in the study was > 600 net ipsilateral turns per
90 min. intervals. This has been shown to correlate with >90% loss
of nigrostriatal dopaminergic innervation [23].
MR Studies:
The MR studies were performed on a 4.7 T GE Omega CSI imaging
system. All of the 6-OHDA lesioned animals were anesthetized with
a halothane/N 2 0/0 2 mixture (1% h'alothane in volume) and imaged
using a 35 mm birdcage coil. All animals were temperature
regulated using a circulating water blanket at 380 C over the whole
study period.
Although the 6-OHDA can produce acute insults in the dopaminergic neurons, the
supersensitivity (upregulation) in the postsynaptic striatal neurons does not begin to appear
until one to two weeks after the lesions. Therefore, the behavioral tests can only be used to
screen out the improperly lesioned animals at least 3 weeks after the 6-OHDA lesions.
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Anatomical Images:
Both conventional spin-echo T 2-weighted sequences and diffusion-
weighted sequences were used to screen for possible abnormalities
such as edema or intracellular swelling. The parameters used were:
1) T 2-weighted images -- TR/TE 3s/80ms, 2 average, 8 slices,
2.2mm slice thickness and 2.3mm slice separation with in plane
resolution of 0.195mm x 0.390mm.
2) Diffusion-weighted images -TR/TE 2.2s/53ms, 2 average, 4
slices with 2.2mm slice thickness and 2.3mm slice separation, in
plane resolution 0.195mm x 0.390mm, diffusion gradients were
[Gx,Gy,Gz] = [4,4,0]gauss/cm, equivalent b value = 500 s/cm 2
(8=12.5ms, A = 20.5ms).
3) Hemodynamic Measurement - In order to study the
hemodynamic properties of the lesioned striatum, measurements of
rCBV and rCBF were made using bolus injections of 0.2mmol/kg
Gd(DTPA) (Magnevist, Schering AG, Berlin) [15,16] and rapid gradient
echo imaging with 1.28 s/image temporal resolution (TR/TE 20/7ms;
Ernst Angle RF).
Chemical Shift of metabolite Images :
The metabolite images were acquired by using a spin-echo chemical
shift sequence (TR/TE = 2s/272ms). This CSI sequence uses a
binomial 1800 RFpulse with null point at 4.7 ppm to suppress the
water signal [24,25] and with the maximum RF power set at 2.023
ppm (the methyl group of NAA). Lipid suppression was done by
using short-TI inversion recovery (STIR) technique with varied
inversion time (TI) [26]. The initial TI value was optimized according
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to individual animal to minimize the lipid signal at the Ky = 0 line.
The inversion recovery waiting time (Ti) was then stepped through
the (Kx, Ky) domain (phase encodings) with 600gs increment. Three
dimensional chemical shift images [f,x,y] were obtained through x
and y phase encodings with in plane resolution = 2.18mm x 2.18mm
(fov 35mm with 16x16 x/y phase encodings) and the spectral
resolution = 7.18Hz (spectral width of 4000HZ with 512 points
digitization). The raw data (t, Kx, Ky) were zero filled to 32 by 3 2
matrix in the Kx and Ky domain, individual spectral line was
modulated by a low pass sine filter and then 3D Fourier transform is
applied to reconstruct the 3D chemical shift images [f,x,y]. The
metabolite images (NAA and lactate) were reconstructed by adding
together the spectral lines containing the desired metabolite peak
and viewed along the frequency axes (a [x,y] image). To avoid the
possible spatial distortion of the spectral lines due to field
inhomogeneities cross the imaging field (i.e., a shift in the spectral
axis [f] at different spatial coordinate [x,y] due to field
inhomogeneities ABo), a homemade program is applied to trace the
spectral location of the metabolite peaks through the spatial domain
to correct for this distortion (i.e., correct the shift in the spectral
frequency axis). The NAA image was reconstructed from the methyl
group signal centered at 2.023 ppm and the lactate image was
reconstructed from the spectral peak centered at 1.33 ppm by
assuming the planes corresponding to the linewidth of the peak
analyzed.
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Data Analysis-
The anatomical images (T 2 or diffusion weighted images) were
overlaid onto the metabolite (CSI) and hemodynamic (rCBV, rCBF)
images to segment the outer contour of the hemispheres and the
striata. The abnormality indices, labn , were then determined as:
labn = (Slips str - SIcont str) / SIcont str x 100 (4-1)
The abnormality indices labn from each animal were then pooled
together to investigate the statistical differences between the control
and ipsilateral striata (paired student t test).
Results:
Water images:
There was no obvious abnormality on either the T2 or diffusion
weighted images of the 6-OHDA lesioned animals (Figure 4-1). This
indicates that the loss of the dopaminergic innervation in the
striatum may just lead to functional impairment but not to a global
morphological modification. This indicates that although there is a
certain degree of abnormality in the dopaminergic supply to the
striatal area, there are no gross tissue abnormalities. In contrast to
this normalcy, other neurotoxins, such as malonate or MPP + induced
striatal lesions, show very early striatal lesions that are detectable
using diffusion weighted images and the mature lesions are not
likely to be missed on T2 weighted images [27]. The hemodynamic
maps (rCBF and rCBV, figure 4-2) from the bolus injection of Gd-
DTPA showed no significant differences in the resting states between
the two hemispheres (and striata), either. The resting rCBV was
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slightly higher in the lesioned striatum but this was not significant (
= 5 ± 27%, p > 0.85) and the rCBF was about equal in both striata ( -
1 ± 11%, p >0.4). This suggests that there may not be much change
in the resting state of regional hemodynamics or any significant
change in vascularization due to the 6-OHDA lesions in the medial
forebrain bundle. The stable resting rCBV and rCBF status are
important and essential in the investigation of the neuronal coupling
between the pharmacological stimulation and the hemodynamic
response, which we will discuss further in the next chapter (chapter
5).
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T2 Weighted Images
ADC Images
Figure 4-1. T2 and ADC weighted image of rat with unilateral
lesioning in the medial forebrain bundle. There is no global
abnormality in the hemisphere ipsilateral to the lesioning.
L: Lesioned side, C: Control side.
Control side
Lesioned side
Significant level
CBV
Control
side
6-OHDA
lesion
1.05 ± 0.27
p > 0 .85
CBF
Control
side
0.99 ± 0.11
p> 0.45
Figure 4-2. Bolus injection of Gd-DTPA shows normal
baseline state in hemodynamic properties (CBV and
CBF, n = 9).
6-OHDA
lesion
2) Metabolite images:
The metabolite images, on the other hand, provide different
information. There was no apparent increase of the lactate level in
either striatum, ipsilateral or countralateral to the MFB lesion. The
neuronal marker N-acetylaspartate (NAA), which is abundant in
healthy neurons, however, showed a decrease in the ipsilateral
striatum (figure 4-3; average = 9.61 ± 0.01%, p < 0.0003; range
between 5 to 21 % signal decrease compared to the control striatum).
Curiously, this signal depletion in the ipsilateral striata extends to the
medial bottom part of the brain. Since the slice thickness for the
metabolite images is 7 mm, and thus we lose the spatial resolution in
the antero-poster0 axis, the signal loss of this tail (marked with a
white arrow in figure 4-3) is suspected to be the track of the medial
forebrain bundle. Similar NAA signal loss and lactate elevation along
this tail have been found in the MPP + lesions via intrastriatal
injection (unpublished data from B. G. Jenkins). MPP ÷ injected
intrastriatally will follow the reuptake pathway of the endogenous
dopamine and be shunted to the substantia nigra via the medial
forebrain bundle.
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NAA Image
Control 6-OHDA
side lesion
Figure 4-3. NAA image on a 6-OHDA lesioned rat. There is
significant NAA signal loss in the striatum ipsilateral to the
6-OHDA lesioning. Note the signal loss extending to the
medial-ventral part of the brain may indicate the tract of
the medial forebrain bundle.
Discussion:
Although we detected no apparent global changes in the T2 and
diffusion weighted images, several investigators have demonstrated
global histological changes following 6-OHDA lesioning.
Immunohistochemical staining with tyrosin-hydroxylase showed that
the afferent dopaminergic terminals ipsilateral to the 6-OHDA lesion
were reduced 90% compared to the normal control striatum.
However, a large dopaminergic projection deficit to the striatum
could lead to many other alterations in the biochemical balance of
the striatal cells. Such alterations include: supersensitivity, i.e.
upregulation of the postsynaptic dopaminergic receptors (DI and D2),
and higher turnover rates in acetylcholine (ACh), serotonin (5-HT),
and the remaining DA. Zhou et. al. [28] demonstrated that following
lesioning of the SNc via 6-OHDA, the dopaminergic neurons are
diminished in the striatal area while the serotonin (5-HT) fibers
showed increased sprouting. Normally, the 5-HT fibers innervate the
striatum sparsely and the globus pallidus densely with a sharp
delineation between the two. The interruption of the dopaminergic
innervation induced the sprouting of 5-HT fibers into the
dopaminergic territories, and the delineation of 5-HT fibers between
the striatum and globus pallidus became vague. Current evidence
also indicates that 6-OHDA lesions may trigger trophic signals or
remove an inhibition for the growth of 5-HT neurons which may
initiate the sprouting of 5-HT in the nigra as well as in the striatum
[28,29]. Although the role and the mechanism of the remodulation
and rebalance of various neurotransmitter systems after the striatal
dopaminergic dennervation is not clear, it may play an important
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role in maintaining the integrity of the striatal function after
lesioning of the nigrostriatal pathway.
Although the NAA depletion in the ipsilateral strata is highly
significant compared to the control striata in our study, literature has
not reported significant neuronal loss in the striata of 6-OHDA
lesioned animals [30] or from postmortem histology of idiopathic PD
brains. This raises the question that the NAA loss in our metabolite
study is caused by the degeneration of those dopaminergic terminals,
or that there are some other factors which may lead to the NAA
signal loss. That the NAA signal in the striatum ipsilateral to the 6 -
OHDA lesion is less than 15% depleted compared to the normal
contralateral striatum may appear surprising since
immunohistological studies with tyrosine hydroxylase staining in the
normal brains show a relatively high population of the TH-positive
cell clusters covering the striatal slices (6-OHDA kills cells that stain
positive for tyrosine hydroxylase). However, since more than 90% of
the striatal neurons are gabaergic instead of dopaminergic and the
overlap of Nissl-stain and TH-stain show that the high TH-positive
cells are clustered at the areas with low Nissel-stain density
[31,32,33]. In other words, the striatal cell organization is
heterogeneous and the average volume density does not reflect real
local neuron density (neuron counts). The dopaminergic neurons,
which seems to be diffuse and widely covering the striatal section in
the TH-stain, may not be the major fraction of the total striatal
neuron population. In this sense, the 9.6% NAA in the ipsilateral
striatum depletion from the chemical shift images may just reflect
the net neuronal loss after accounting for the degeneration of the
dopaminergic cells, the resprouting of the 5-HT fibers which might
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be expected to increase NAA, and the real neuronal population. Or,
since NAA is higher in neurons with long axonal projections such as
the SNc neurons, the NAA loss may just represent the loss of the SNc
Dopaminergic terminals[34].
The other possible factor leading to the NAA signal depletion is an
increase in susceptibility mismatch, which may be induced by extra
iron accumulation in the ipsilateral SNc and striatum. As we
discussed in chapter 1, one hypothesis about the etiology of
Parkinsonism is that iron deposition in the SNc may lead to or
accelerate the death of the dopaminergic neurons [5,3 5,3 6,37 ].
Oestreicher et. al. also showed that 6-OHDA lesions in the medial
forebrain bundle lead to higher iron contents in SNc[38]. Since iron is
paramagnetic and may introduce an extra susceptibility factor into
the R2* relaxation rate of NAA, it may lead to the NAA signal
depletion if there is extra iron in the ipsilateral striatum. This extra
AR2 * term may not play an important role in the water images (T2
and diffusion weighted images) due to the much shorter T2 of water.
We have performed water R2 * measurements in one of our 6-OHDA
lesioned animals and found no significant changes in R2 *.
For the energy impairment marker lactate, there was no significant
difference between striata in our 6-OHDA lesioned animals (both are
in the baseline levels). However, as we could only examine the 6 -
OHDA lesioned animals at a minimum of 3 days after the medial
forebrain bundle lesioning, any lactate generated during cell death
would likely have been washed out by the time we performed the
chemical shift images. Jenkins et. al. [27] has shown the general
lactate time courses involved in striatal excitotoxicity. The lactate
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level started to build up steadily while the energy impairment
occurred with intracranial injection of the neuronal toxins malonate
or MPP +. Then the lactate level reached a maximum value and
started to decline to the baseline level over the course of
approximately 1 ~ 24 hours. The 6-OHDA lesioning of the medial
forebrain bundle is likely to be similar to these models and hence b y
the time we were able to acquire the metabolite images, we may
have missed the peak of lactate and only detected the post-
impairment stage with no lactate left. However, the 'H-MRS with PD
patients showed elevation of striatal lactate level. Since the disease
progress in PD is a slower process, we may have the chance to
monitor the lactate level over a much longer time period than in the
animal model with acute lesioning. The lactate level shown in PD
patients may indicate the slow energy impairment process instead of
the near completion of cell death.
Conclusions:
The 6-OHDA lesions in the medial forebrain bundle interrupt the
dopaminergic supply from the SNc to striatum and can mimic some
of the symptoms of Parkinsonism in rats. However, the 6-OHDA
lesions induce an acute abnormality in the dopaminergic supply to
the striatal area in contrast to the chronic slow degenerative process
in idiopathic Parkinsonism. The 1H MRS studies in the idiopathic PD
patients (chapter 3) showed elevated striatal lactate levels while the
6-OHDA animal model showed no significant elevation. The cause of
this difference may be the result of a progressive degenerative
process of PD versus the acute insult of the 6-OHDA model.
Nonetheless, neither the PD patients nor the 6-OHDA animals showed
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brain atrophy or anatomical abnormalities compared to normal
controls. This suggests that the abnormalities of Parkinsonism may
not be induced by a massive striatal neuronal abnormality but may
just caused by the malfunction of the minor neuronal population, the
dopaminergic terminals in the striatum. To explore these issues
more deeply, we have to investigate the coupling between the
dopaminergic receptor system and the regional cerebral
hemodynamic responses. In the next chapter (chapter 5), we will
use the 6-OHDA model again to investigate the neuronal activity-
regional hemodynamic coupling by the pharmacological stimulation
induced by the dopaminergic agonist d-amphetamine and the
dopaminergic reuptake blocker CFT.
Appendix -- Behavioral Rotational Test
After unilateral 6-OHDA lesioning in the medial forebrain bundle, the
insufficient dopamine supply to the ipsilateral striatum will induce
supersensitivity, an increase in the number of postsynaptic
dopamine receptors. The degree of dopamine-receptor coupling in
each striatum will be proportional (though not necessarily linearly)
to the number of dopaminergic receptors on the postsynaptic side.
Since each hemispheric motor cortex circuit of the brain controls the
motion on the contralateral side of the body, the animals will turn
ipsilaterally to the 6-OHDA lesioning with the stimulation of D-
amphetamine (a dopamine releaser and reuptake blocker [39]) due
to the loss of dopaminergic innervation in this striatum. More than
600 ipsilateral turns in 90 minutes indicates more than 90% loss of
the dopaminergic innervation in the striatum ipsilateral to the 6-
OHDA lesioning. While more than 900 ipsilateral turns in 90 minutes
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indicates more than 95% innervation loss. On the other hand, if
injected with apomorphine, the dopamine agonist, due to the
supersensitivity built up in the striatum ipsilateral to the 6-OHDA
lesioning, the animal will turn contralateral to the lesion. According
to the literature [40,41,42], the ipsilateral SNc of an animal with a
partial lesion of the medial forebrain bundle will synthesize more
dopamine than the normal level to compensate for the insufficiency
in dopamine transport from SNc to striatum. Therefore, the
dopamine level in the ipsilateral striatum may not show any
abnormality until the loss of the dopaminergic neuronal terminals in
the striatum is greater than 85%. This contention has been tested
experimentally [see fig 3 in ref. 40].
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Chapter 5 Pharmacological MRI (ph MRI)
Introduction
Detection of specific neurotransmitter activity non-invasively and
longitudinally could be of great assistance for understanding brain
pathology and subsequent therapy of many disease processes. For
instance, the destruction of the nigral dopaminergic innervation of
the striatum in Parkinson's disease and subsequent therapy using
fetal cell transplantation would be greatly aided by a means of
following progression of the graft. Studies of receptor binding can be
performed in vivo using positron emission tomography (PET)
imaging, or can be performed post mortem using autoradiography.
These techniques allow one to use receptor agonists or antagonists to
directly map out the receptor density of these binding sites in the
brain and also allow for investigation of the drug induced neuronal
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metabolic changes such as changes in regional cerebral blood flow
(rCBF) or regional glucose utilization (CMRglu) induced by stimulation
of drugs such as d-amphetamine [1,2,3,4,5]. However PET is
compromised in its ability to evaluate humans longitudinally due to
the radioactivity involved in the in vivo studies. The technique of
functional magnetic resonance using either BOLD or T,-based
techniques has led to a revolution in brain mapping. These
techniques are based upon the coupling between neuronal activity,
metabolism and hemodynamics leading to changes in MR signal
intensity sensitive to these parameters [6,7,8]. The technique has
been labeled as functional MRI or fMRI and has been widely applied
to task initiated brain functional studies. In addition to neuronal
activity induced by task activation, stimulation of neurons using
pharmacological ligands is also possible. The use of fMRI to perform
such experiments is tempting due to its non-invasive repeatable
nature. However, due to the large doses necessary to obtain a
response measurable by MR techniques, compared to
autoradiography or PET, it is necessary to ascertain that the
measured response is due to activation of the neurotransmitter
system in question. There are a number of issues which arise in this
context which are relevant to understanding the coupling between
neurotransmitter binding and the hemodynamic response. The issue
of whether the potential fMRI response is due to direct
neurotransmitter binding or indirect effects (such as a change in
pCO2) needs to be investigated. One approach to solving this
problem would be delineation of the correlations between the
hemodynamics, the receptor binding, neurotransmitter release and
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behavior. Several useful techniques exist for studying these events
including PET imaging [9,10] and microdialysis [1 1].
We have chosen to study the dopamine system to examine the utility
of fMRI for investigation of neurotransmitter activation for a number
of reasons. The dopamine system, unlike the glutamatergic, for
instance, shows great regional specificity with high receptor density
in the frontal cortex and basal ganglia. In addition, very
reproducible animal models of dopaminergic binding and ablation
exist. These models are of great interest in studying
neurodegeneration (Parkinson's disease) as well as, for instance, drug
abuse (cocaine addiction). The ability to selectively and unilaterally
denervate the dopaminergic system using 6-hydroxydopamine (6-
OHDA) also allows for a controlled experiment to measure the
efficacy of whether or not the phMRI response is due directly to
dopamine. There is a large body of autoradiographic data on the
response of both rCBF and glucose utilization rates to dopaminergic
ligands such as d-amphetamine, as well as a wealth of behavioral
and autoradiographic data on the 6-OHDA model [12,13]. We have
utilized two different dopaminergic ligands. D-amphetamine is a
dopamine release compound which appears to work by increasing
the dopamine concentration in the synapse by release of dopamine
from the transporter receptor [14]. CFT (23-carbomethoxy-33-(4-
fluoropheny) tropane, or 1 1C-WIN 35,428 compound) is a dopamine
transporter antagonist whose effects are much like cocaine, only
more specific [15,16]. We demonstrate here that the fMRI response
to pharmacological stimulation (hereafter dubbed phMRI) shows a
tight coupling to the regional distribution of dopamine transporters
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using PET and to the release of dopamine as studied using
microdialysis.
Methods
Animal preparation-
Unilateral medial forebrain bundle lesions with 6-OHDA were
processed and tested as mentioned in the animal preparation session
in chapter 4. The successfully lesioned animals (n = 18) and normal
control rats (n = 5) were scheduled for both PET and MRI studies. Six
dopaminergic fetal cell transplanted rats were included in this study,
too, to validate the tight correlation between the phMRI responses
and the dopaminergic neuronal activities. The success of the graft
can be assessed by behavioral testing using the amphetamine
rotational test described in the last chapter (see appendix in chapter
4). Unfortunately, due to the tremendously long preparation time for
the 6-OHDA lesioning plus the fetal cell transplantation, no baseline
studies (MR or PET ) could be done in the graft recipients before the
neuronal transplantation.
MR Measurements-
All MR measurements were performed on a 4.7T GE Omega CSI
imager (Fremont, CA). Animals were imaged using a 35mm birdcage
coil under halothane/N20/02 anesthesia (1.5% halothane). All
animals were temperature regulated using a circulating water
blanket at 380 C and were monitored for arterial oxygen saturation
using a Nonin pulse oximeter (Minneapolis, MN) during imaging. The
immobility of the animal during the drug stimulation and the
homogeneous signal intensity of the gradient echo images over the
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whole brain tissue were two critical conditions for the success of the
phMRI studies. To attain these goals, the animal heads were shaved
and wrapped with either dental hydroplastic gel or water-soluble
bathroom adhesive caulk to immobilize the head and to reduce the
susceptibility differences created by the tissue-air interface. The
rats were imaged using conventional gradient recalled echo images
acquired repeatedly from the striatal area (TR/TE 400ms/15ms,
Ernst angle RF, 3 or 5 slices with slice thickness 1.5mm). At least 1 5
stable base line image sets were acquired before the pharmacological
stimulation. Three mg/kg D-amphetamine or 0.75mg/kg 23-
carbomethoxy-3p3-(4-fluoropheny) tropane (CFT, or WIN 35,428
compound, RBI, Cambridge, MA) were then given intravenously
while the images were being acquired, the imaging was continued
for 90 to 180 minutes post injection. In addition to the blood
oxygenation saturation monitoring, an arterial line from the femoral
artery was connected to a cardiac monitoring device (706 patient
monitor, Ivy Biomedical System Inc.) in the nonlesion control group.
The mean blood pressure and heart rate were recorded every 3
minutes and the arterial blood gases (pO2, PCO2, and pH) were
sampled in 15 minute intervals. However not all animals, especially
for the rats with 6-OHDA lesions and the group with grafts, could
have blood sample or blood pressure monitored during MR scanning
due to the impossibility of performing the necessary survival studies
with the surgery required to insert the femoral arterial line.
In addition to the MR study, another control population of animals
was studied on bench tops under similar physical conditions as the
in-magnet studies (using 1.5% halothane anesthesia, body
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temperature regulated, blood oxygenation monitored, etc).
Measurements of blood gases (pO2 , pCO 2, and pH), heart rate and
blood pressure were obtained the same fashion as the in-magnet
studies over two-three hour time periods including baseline and post
pharmacological stimulations (3mg/kg amphetamine i.v. or
0.75mg/kg CFT i.v.).
PET Measurements-
The same animals studied by phMRI were also scanned using
positron emission tomography (PET). Anesthetized animals were
placed on an imaging table. The head was secured in a customized
Plexiglas head holder equipped with ear and mouth bars designed to
ensure reproducible head positioning in PET. Imaging studies of
dopamine transporters were performed using carbon-11 labeled CFT
as a tracer. For PET imaging 0.8-1.2 mCi of the labeled compound
(specific activity 800-1600 mCi/mmol) was administered into the tail
vein. Serial dynamic imaging was acquired over the rat brain for 60-
90 min using 4.5 mm steps and counts were block averaged for
between 15-60s intervals depending upon how far along the 20 min
half life "C decay curve the measurement occurred. PET Imaging
was performed using a home-built high resolution single ring
tomograph, PCR-I described earlier [17]. The resolution of PCR-I for
a point source at the center is 4.5 mm and the sensitivity is 46,000
Hz for a source of 20 cm in diameter with a concentration of 1 mc/cc.
The overall efficiency is 64% of the theoretical maximum for a plane
thickness corresponding to the 2 cm high crystals. The plane
thickness of 4.5 mm used in this study was obtained by the use of
cylindrical collimators which limit the effective height of the crystals.
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Imaging data were corrected for uniformity, attenuation, decay and
acquisition time. Images were reconstructed using a ramp filter with
a cut off value of 1.0 and convolution back projection.
Microdialysis --
The extracellular dopamine concentration from the dorsal lateral
striatum was accessed by using microdialysis. For amphetamine
stimulation, we used the existing data of dopamine release from
literature [11,18,19]. For CFT stimulation, home made glass dialysate
probes were implanted into the dorsal lateral striatum in the normal
control rats. The dialysates were collected in 20 minute time blocks.
The same CFT protocol as in the fMRI study was followed in the
microdialysis study (40 minutes baseline and 90 minutes post CFT
injection.) HPLC was used to analyze the dopamine concentration in
the dialysis. Unfortunately, because of the invasiveness of this
procedure, we can not perform microdialysis longitudinally and we
used a different set of control animals than the fMRI study.
Data Analysis-
The activation maps of the phMRI data sets were generated using
Komolgorov-Smirnov statistics and overlaid on the gradient echo
images. Two approaches were utilized to define the activation.
Areas of activation as defined by the statistical maps were calculated
using automated segmentation of the maps at a predefined threshold
of p < 0.01 (determined by requiring at least four activated pixels to
be significant). The percent signal changes were also measured in
these areas as well. In order to determine specificity, the anatomic
structures were segmented using a rat brain atlas [20]. The fraction
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of each structure activated, as determined from the statistical maps
was then calculated. The differences between the ipsilateral and
contralateral hemispheres were then measured using both the
percent signal change and the areas as
Contralateral - Ipsilateral
Contralateral
These numbers were then compared with the PET data by averaging
together the three 1.5 mm MRI slices to obtain the same slice
thickness as in the PET studies.
For analysis of the PET data, since there is very little specific
dopaminergic binding occurred in the cerebellum, the signal changes
in cerebellum are assumed to represent non-specific binding and
hence can be used to normalize the signal responses in other brain
areas such as striatum. Regions of interest (ROI) including left and
right striatum and cerebellum were drawn and the percent activity
of the injected dose was calculated. Binding ratios of "C-CFT into the
dopamine transporter were calculated according the following
formula:
(Percent Activity Percent Activity
Binding rati # of Pixel ]str - # of Pixel IcerebellumBinding ratio Percent Activity
# of Pixel )cerebellum
The values of the binding ratios were averaged between 55 and 6 5
min (so as not to include the initial activity due largely to flow) and
compared to the values of hemodynamic indices from MR studies as
well as to rotational behavior using the amphetamine stimulation
described above.
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Results
The injection of either amphetamine or CFT caused an increase in
signal intensity using BOLD imaging that was regionally localized to
areas of the brain that are high in dopaminergic receptor density as
shown in Fig. 5-1. These areas include cingulate and frontal cortex
(but not parietal cortex) and striatum. Initially, we used higher
doses of amphetamine which led to non-specific increases in all areas
of the brain as also reported by Silva et al. using 20 mg/kg
amphetamine [21]. The dose of 3mg/kg i.v. of amphetamine
produces an phMRI response which is similar to that produced by
0.75 mg/kg of CFT. The regional specificity of brain activation was
measured by automated segmentation analysis of the statistical maps
generated by analysis of the time courses and measuring the fraction
of the anatomic structure activated. These results are shown in Fig.
5-2. It is clear that the frontal cortex and the striatum are the areas
which show the largest activation, in keeping with their large
dopaminergic innervation. Parietal cortex which is relatively low in
dopamine innervation has relatively low fMRI response. The reason
why the parietal cortex activation is not zero may be due to the
partial volume averaging of our relatively thick slice (1.5 mm).
Figure 5-3 illustrates the parietal cortex in the mid-striatal slice is
overlapped with the striatal area in the more posterior slice. The
overlap is 10% in the parietal area.
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Figure 5-1 Statistical maps of increased BOLD signal change in
normal control rats after injection with (A) 3 mg/kg amphetamine or(B) 0.75 mg/kg CFT. Changes in blood pressure and pCO2 as
measured in the magnet are shown with the percent signal changes.
Note the BOLD signal change is delineated from blood pressure and
pCO2 changes.
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Figure 5-2 Bar graph showing the fraction of anatomic area activated
by either amphetamine ( n = 18) or CFT (n= 12). Segmentation was
performed as described in text. A schematic of the areas segmented
is shown. 1. frontal cortex, 2. striatum, 3. cingulate cortex, 4. parietal
crotex.
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Fig. 5-3 Partial volume averaging in the parietal cortex. Yellow
area with black line indicates the contour of the slice from the
mid-striatum. Red line indicates the contour from the more
posterior slice. The slice thickness in this study is 1.5 mm with 0
mm gape between slices.
Analysis of the time courses show that the response of the phMRI is
transient, peaking at about 40 min and decreasing back to the
baseline in about 70-90 min. This time course has the potential to
reveal much about the nature of the effect. We thus performed a
number of experiments. Shown in figure 5-4 are the effects of
amphetamine and CFT on blood gases and blood pressure. It is clear
that the time courses for these changes do not parallel those of the
phMRI response as seen in figure 5-1. The effect is clearly not due
to increased pCO2 or the transient spike seen in the blood pressure
curves.
In order to show that the time course of fMRI signal changes
parallels the time course for release of dopamine in the dorsal-lateral
striatum, we block averaged the fMRI time courses with time bins
corresponding to the microdialysis data points. As shown in figure
5-5, the fMRI time course is virtually superimposable with the
release of dopamine measured by microdialysis (Fig. 5-5 A) and is
well correlated to the percent change in extracellular dopamine
concentration (Fig. 5-5 B).
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Figure 5-4 Changes in blood pressure and pC02 for all the animals
pooled for amphetamines and CFT.
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Figure 5-5 phMRI time points are block averaged with time bins
corresponding to the microdialysis data points. (A) amphetamine (C)
CFT stimulation. (B) and (D) show the correlation between the
percent phMRI signal changes versus percent increase in dopamine
release.
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Destruction of the dopaminergic input to the frontal cortex and
striatum should lead to an ablation of the phMRI response. This is
shown in Fig. 5-6 using both amphetamine and CFT. Responses
typical of the greatest, average and least differences between the
ipsilateral and contralateral sides are shown in this figure in order to
get an indication of the reproducibility and range of responses
measured. Two time courses of the signal changes seen in the
animals shown in Fig. 5-6 are presented in Fig. 5-7 for amphetamine
and CFT. It is apparent that the response is much decreased on the
ipsilateral side. To prove this was not due to an artifact, such as loss
of regional blood flow or hemodynamics, we measured these latter
parameters (rCBV and rCBF) using bolus injections of Gd(DTPA) [22,
23]. There was no statistically significant difference in the resting
rCBV or rCBF between the two hemispheres indicating that the
decreased phMRI response is not due to a decrease in the pre-
stimulus values of these parameters on the ipsilateral side as shown
in the previous chapter. These data are presented, along with rCBV
and rCBF images in Fig. 5-8. In order to compare the phMRI response
to behavioral changes, we time binned the fMRI time courses to
correspond to the behavioral data (figure 5-9 A). The fMRI signal
changes in the striata ipsilateral to the lesioning parallel the time
courses of the rotational behavior in these animals. Figure 5-9 B also
shows that the time course for the behavioral data of the unilaterally
lesioned rats also correlates well with the extracellular dopamine
concentration.
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Figure 5-6 phMRI responses of the unilaterally lesioned rats
with stimulation of (A) amphetamine (B) CFT. Shown here
are rats with good to bad phMRI reponses (top to bottom).
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In order to investigate the relationship between the dopamine
transporter receptor and the phMRI we decided to run PET
experiments on the same animals studied using the phMRI
techniques above. The comparison between the PET results and the
phMRI results was, in general, very consistent. In the lesioned
animals a loss of "C-CFT uptake is noted in the ipsilateral striatum,
compared to the unlesioned, control animals (Fig. 5-10). The phMRI
results faithfully reproduce this finding as is also seen in Fig. 5-8.
The average change in the parameter describing the percent
difference between the ipsilateral and contralateral striatum
(contralateral -ipsilateral)/contralateral) was 39 ± 4% for PET and
the decrease in phMRI response to amphetamine or CFT stimulus was
39± 16% (n=12; p < .001) and 42± 18 % (n=18; p < 0.001) respectively
when measured as change in areas (figure 5-11). However, there is a
large decrease in this asymmetry post transplantation [PET = 20.90±
8.64 % (n=9; p >0.25), fMRI with CFT = 15.76± 3.66 % (n=9; p >0.35)].
Obviously because the grafts are much smaller than the total
striatum, we may not get return of full symmetry even though there
was a full behavioral recovery for all transplanted animals. The
good correlation with the PET images clearly indicates that the
decreased binding of both CFT and amphetamine to the dopamine
transporter is well reflected by the metabolic response as shown by
phMRI. Although the rats were screened by rotational data to
correspond to those with greater than 95% loss of dopaminergic
nigro-striatal innervation, there were clear differences in the
number of rotations between animals. Thus, we looked to see if the
behavioral data had any correlation with the imaging data. We
compared loss of CFT binding in the ipsilateral striatum using PET or
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metabolic response using phMRI as [(Contralateral
Ipsilateral)]/Contralateral) The correlation between the PET, the
phMRI and the behavioral data (rotation) is shown in Fig. 5-12. It is
clear that there is a weak, but significant, correlation between the
rotation and the PET. There was a strong correlation between the
CFT and rotation, but none with amphetamine.
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Figure 5-10 PET images and the corresponding phMRI images from a
6-OHDA lesioned and a neuronal transplanted animal. PET images
come from a slice centered on the striatum. There is good
correspondence between the PET images of CFT uptake and the
phMRI images of the metabolic response, with the exception of the
cortical regions.
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Figure 5-11 There is big asymmetric response in the two
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Discussion:
We have demonstrated that the techniques commonly employed for
fMRI studies of brain function during task activation are also
appropriate for examination of the effects of neurotransmitter
receptor stimulation. We utilized a well characterized model of
dopamine denervation to show that the metabolic response resulting
from stimulation of the dopamine system is well circumscribed to
those areas of the brain containing large dopamine innervation and
that the response is ablated when the nigro-striatal dopamine
connections are denervated. There are a number of issues which
need to be addressed before studies of this nature become routine
both for the dopamine system in particular; and other
neurotransmitter systems in general. The fact that we are observing
a metabolic response to neurotransmitter binding rather than the
binding itself, as in PET, creates some problems. One problem is that
the large doses necessary to see an effect may lead to non-specific
effects. This problem is especially acute in the dopamine system
because of the possibility of stimulating other monoamine systems in
the brain using a compound like amphetamine [1,2,3,4]. Another
problem is understanding the coupling between the changes in the
hemodynamics with the changes in dopamine concentrations. If the
metabolic response is only coupled by very indirect means to the
neurotransmitter release then the phMRI technique is not as useful
as if there is a direct correlation.
Our results shed light on these problems. First, the spatial specificity
we observed in our phMRI results with high fMRI responses in those
brain areas with high dopaminergic innervation and the nice
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correlation between fMRI and microdialysis data indicate that the
fMRI effect is primarily due to dopamine and not other monoamine
systems which would lead to more non-specific cortical activity. This
is indeed what we observed with higher doses of amphetamine and
has also been seen in autoradiographic studies of CBF [1,2,3,4].
Secondly, we showed that the time course for the signal changes are
not reflective of simple physiological changes like hypercapnia,
further indicating that the response is due to a metabolic response to
neurotransmitter binding. Denervation of the dopaminergic input to
the striatum using the well known model of 6-OHDA also showed
that the response was due to dopamine as the change in signal
intensity was nearly ablated on the ipsilateral side for both
amphetamine and CFT. Measurements of resting rCBV and rCBF
using bolus injection of Gd(DTPA) showed this was not due to
impairment of vascularization or hemodynamics on the lesioned side
The dopaminergic denervation in the ipsilateral striatum was also
demonstrated using PET imaging of 11C-labeled CFT, thus lending
more credence to the origins of the phMRI signal differences in the
ipsilateral and contralateral striatum. The mean values of the
percent differences ((Contralateral - Ipsilateral)/Contralateral) for
both the PET binding and phMRI percent signal changes were
identical. While it is not clear at this time how to turn PET binding
measurements into blood flow changes, nonetheless the tight
coupling between loss of CFT binding as measured by PET and loss of
BOLD signal change using the 6-OHDA model indicates that the
coupling between these two parameters may be quantitative.
In this regards it would be instructive to evaluate other pulse
sequences to examine rCBF using T,-type techniques [7,21,24] as well
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as BOLD. If there are dissociations between flow, oxygen
consumption and glucose utilization these should show up as
differences in these two signal responses. We initially tried using IR
and GE sequences in these experiments in an interleaved mode for
amphetamine stimulation, but came to the conclusion that the
statistical power was not sufficient given the relatively low SNR of
the images. Use of EPI techniques would alleviate this problem, but
our current implementation of EPI involves a tradeoff of spatial
resolution for temporal resolution (1 mm vs. 0.25 mm in plane
resolution) which makes it difficult to adequately segment structures
such as the cingulate and the accumbens in the small rat brain.
The time course noted for the phMRI signal changes are quite similar
to those seen using microdialysis measurements [11,18,19]. In
particular, the peak time for dopamine release measured using
similar doses of amphetamine corresponds exactly to the peak of the
phMRI response at about 40 minutes. This implies that the phMRI
response is due to the release of dopamine in the striatum.
The sum of these facts, and the loss of phMRI response after 6-OHDA
lesioning, strongly suggests that the metabolic response is due
primarily to the release of dopamine in the striatum. In this regards
it is instructive to compare the behavioral and PET data to the
phMRI. As shown in Figs. 5-9, 5-11 and 5-12 there was a good
correlation between the PET, rotation and CFT phMRI results. This
was somewhat surprising as, according to the literature, rotations of
greater than 600turns/90mins should reflect greater than 95%
dopamine cell loss in the striatum [12,25]. Since all our rats were
screened to manifest this behavior, the amphetamine results we
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obtained (i.e. no correlation with behavior) were what we expected.
The fact that we observe correlations of behavior with PET and
phMRI using CFT implies that the some dopamine transporter may
still be present in spite of the supposed loss of the pre-synaptic
terminals. There is some precedent for this in the microdialysis
literature, as when one measures extracellular dopamine levels
versus percent dopamine neuronal depletion, there is a good deal of
scatter - even for animals with nearly complete lesioning (see Fig. 3
in ref. 19 ). This same inter-animal variability has also been seen in
behavioral/histological studies [25]. This finding has also been
observed in PET studies of CFT binding in an MPTP model of
Parkinsonism in primates where CFT uptake is sometimes still seen,
even after lesioning (Brownell et al., unpublished ).
The sensitivity manifested by the phMRI technique may make it a
useful tool for pre-screening of Parkinson's disease in the earlier
stages. Since symptoms of PD do not seem to occur until roughly 80%
of the dopaminergic innervation of the striatum is destroyed, there is
the possibility of being sensitive to changes that are on this order.
This technique may also prove useful for evaluation of other
dopamine ligands such as D1 and D2 agonists and antagonists. The
ability of MRI to be used longitudinally and repeatedly may enable
one to study up and down-regulation of the dopamine receptors over
time. This could be of great interest in phenomena such as drug
abuse. In addition, the possibility of examination of other
neurotransmitter systems is quite feasible and will prove to be a
fruitful area for future investigations.
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Conclusions:
We show here that use of the dopamine transporter agonist CFT and
the dopamine release agonist, amphetamine, cause a hemodynamic
response to dopaminergic stimulation which has the following
features: 1) The response is regionally specific to those areas of the
brain with highest dopaminergic density; 2) The time course follows
the time course for release of dopamine in the striatum via
microdialysis; 3) The response is selectively ablated via unilateral
lesioning of the nigral-striatal tract using 6-OHDA; 4) The response is
well correlated with in vivo PET and histologic measures of
dopaminergic transporter binding as measured using "C-CFT; and 5)
the response is restored in those same animals using neural
transplantation of fetal mesencephalon cells into the striatum.
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Chapter 6 Thesis Summary and Future Work
The primary objectives of this thesis were to investigate and verify
neurodegenerative processes. We focused primarily on Parkinson's
disease (PD) to evaluate the possible neurochemical modulation and
the neuronal responses caused by disturbance of the dopaminergic
system in the movement disorder of PD.
Although the Parkinsonian symptoms have been well documented
and described since the 19th century, the etiology of PD is still
unclear. Human evidence includes drug abusers who received MPTP
and subsequently developed signs and symptoms resembling
idiopathic PD[1]. Further studies showed that MPP +, the metabolite
of MPTP, can block the enzymatic activity of complex I in the
electron transport chain. This human evidence suggests that PD may
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be associated with dysfunction of mitochondrial respiration in the
basal ganglia [2,3]. Blockade of the electron transport chain may lead
to cessation of the TCA cycle, which in turn leads to accumulation of
lactic acid [4]. This provides us an opportunity to monitor the lactate
levels in the PD brains by using 'H-MRS. The lactate level in the
resting state of a normal brain is nearly undetectable using 'H-MRS
and any extra accumulation of cerebral lactate in the resting state
may indicate an abnormality in energy respiration. In this thesis we
tried to measure the cerebral metabolites in PD brains and normal
age-matched subjects by using 'H-MRS.
Although the energy impairment theory may provide valuable
information regarding neuronal degeneration, the question of how
this neuronal degenerative process is associated with movement
disorders is yet to be answered. In order to understand the
mechanism involved in basal ganglia function better, one has to
investigate the neurotransmitter system as well. Postmortem studies
of PD brain show neuronal loss in the substantia nigra pars compacta
(SNc) [5,6]. Functionally, the neuronal loss in the SNc will lead to
alterations in the striatal dopaminergic innervation. However, data
from both PD patients and animal models of PD show that th e
Parkinsonian symptoms will not start to show up until there is about
80% to 90% loss of the dopaminergic innervation in the striatum
[5,6,7]. To mimic the abnormal dopaminergic innervation in the
striatum, we used a well studied animal model with injection of 6-
hydroxydopamine (6-OHDA) to selectively and unilaterally deplete
the striatal dopaminergic innervation [8,9]. This animal model allows
us to investigate 1) the possible striatal metabolite changes after the
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dopaminergic denervation, and 2) to assess the regional
dopaminergic activity in brain. The striatal metabolites can be
assessed using 'H-MRS technique. In this thesis, we chose to use 3D-
chemical shift imaging technique (3D-CSI) which allowed us not only
assess the cerebral metabolite information but also the spatial
distribution of those metabolites over the whole brain. The regional
dopaminergic activity can be assessed using functional MRI (fMRI)
with the stimulation of specific dopaminergic ligands. We dubbed
this technique as pharmacological MRI or phMRI.
The main goals of this thesis are 1) to accurately evaluate the
cerebral metabolite levels using 'H-MRS, and 2) to validate the
possibility of using fMRI to assess the neurotransmitter activity. In
order to evaluate the cerebral metabolite level accurately, we
investigated in this thesis the conditions that may alter the accuracy
of spectral analysis. We used computer simulations to synthesize 'H-
MR spectra under various magnetic field strengths and
homogeneities. We also evaluated the possible errors involved in
both relaxation times and absolute concentration measurements.
Only accurate spectral analysis allows us to have a reasonable
comparison in the cerebral metabolite changes between the normal
and disease states.
Technical Concerns in using 1H-MRS to explore the striatal
metabolites
The utilization of 'H-MRS to quantify the metabolic concentration in
the striatum involves several technical difficulties, such as spectral
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overlap, low signal to noise ratios (SNR) and relaxation rate
measurements. We used computer simulations to demonstrate how
each factor alters the estimation of the relaxation times and the
absolute metabolite concentrations. We found that it would be
difficult to obtain accurate relaxation times T, and T2 because of
spectral overlap, macromolecular contamination [10,11] and J-
coupling. The T2 measurement is usually achieved by multi-echo
spin echo experiments and the signal intensity will be a mono-
exponential decay as function of TE. With spectral overlap, the signal
decay is no longer a mono-exponential. When the overlap involves J-
coupling, the decay curve oscillates in a sinusoidal fashion which
makes the T2 relaxation time measurement even more complicated.
Our computer simulations showed that the T2 error could be as high
as over 100% and the error does not depend on the number of TE
points chose in the measurement and there are no magic TE values
one can use to minimize this error.
When propagating the relaxation time error into the estimation of
the metabolite concentration, we found that the T, error of NAA is
more critical than the T, errors of water. The percent error in the
NAA concentration caused by the T, error of NAA is between 45% to
65% as a function of TEs. The error essentially comes from the
saturation factor and the longer the T, value is (T1NAA > Twater), the
greater error will be in the concentration measurement ([NAA]
ErrorTINAA > [NAA] ErrorTiwater ). This T, error factor could be
minimized by using a longer TR value. When TR is longer than 3 sec,
the concentration error due to T, error can be ignored. However,
none of the concentration errors propagated from the T2 errors of
155
water or NAA can be neglected. The T2 errors can make the error of
the NAA concentration as high as over 100%. Therefore, the accuracy
of T2 measurement is much more important than the accuracy of T,
measurement in estimating the absolute metabolite concentration.
Although our computer simulated spectra showed great similarity to
the in vivo and the phantom spectra, our simulation was only based
upon the assumption of weak J-coupling and lack of macromolecular
components. Future work would add in these two factors to the
computer simulations. It is also important to investigate the J-
coupling effects under the influence of different pulse sequences.
In conclusion, absolute metabolite concentration measurements may
have been a great objective but are not practically reliable. We
believe that the relative concentration measurements [12] may
provide more useful and reasonable comparisons for quantitative
analysis, especially for inter-laboratory comparisons.
1H-MRS in PD patients and animal model of PD
The hypothesis that disruption of the electron transport chain in the
basal ganglia may be responsible for the movement disorder in PD
was assessed by monitoring the lactic acid level. We chose to
examine the striatal lactate level in both PD patients and age-
matched normal controls using a spatially localized 'H-PRESS
sequence. We also examined the lactate level in an animal model of
PD (6-OHDA lesioning) using a 3D-CSI technique.
In the human study, we found that the striatal lactate level in PD
patients was elevated 59% compared to normal controls (p <0.0004).
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No other major 'H-MRS detectable striatal metabolite showed
significant differences between the PD and the normal control
groups. We also found a significant lactate asymmetry in the two
striata for both PD patients and normal controls (p < 0.02). Just
comparing the lactate levels on the largest side, the PD patients
showed a significant increase in the lactate level compared to the
normal controls (64.51% increase, p <0.05). Interestingly, most of
the subjects (PD and normal controls) have a higher lactate level in
the left striatum. Since most of the people are left hemisphere
dominant, and the left hemisphere has long been hypothesized to
govern the mental computation, language, and motor tasks. The left
striatum thus has been hypothesized to have a heavier working load
than the right striatum. The higher neuronal firing incident rate in
the left striatum may lead to higher vulnerability with energy insults
and this may be the cause of the asymmetric lactate levels in the two
striata
However, for the 6-OHDA lesioned animals, we did not find
significant lactate elevation in the striatum ipsilateral to the
lesioning. This may be due to the fact that the acute 6-OHDA
lesioning causes cell death too rapidly (i.e. within 24 hours), and
lactate may only be elevated during the first few days post-lesioning.
Since we only studied these animals at least three weeks after
lesioning, we may not have seen lactate for this reason. In contrast,
the neurodegeneration in PD patients is a much slower progressive
process which allows us to monitor the dynamic changes in the
lactate level in a much wider time window. However, the neuronal
marker N-acetylaspartate (NAA) showed a significant decrease in the
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striatum ipsilateral to the 6-OHDA lesioning (9.61%, p <0.0003; range
5-21%). Although histological studies of postmortem PD brain did
not find any significant cell loss in the striatum. The mismatch
between the animal NAA loss and the human histological finding
may represent the rebalance of the degeneration of the dopamine
terminals and the resprouting of the serotonin (5-HT) fibers [13,14].
In other words, the NAA loss may just reflect the net neuronal
population (cell bodies) in the striatum after the 6-OHDA assault.
The other possibility is a susceptibility mismatch due to the extra
iron deposition in the ipsilateral striatum. It has been found that PD
patients and 6-OHDA lesioned animals have relatively high iron
deposits in their brain [15,16]. Iron is paramagnetic and can induce
AR2* changes and alter the signal intensity of NAA. This extra AR2*
term may not play an important role in the water images (T 2 and
diffusion weighted images) due to the much shorter T2* of water
than NAA.
Overall, 'H-MRS provides reliable access to the in vivo cerebral
metabolites. Although our studies showed elevated lactate levels in
PD patients, which did not correlate with age, disease severity, DOPA
dose administered of the duration of PD, there are still other possible
clinical variables which may influence the lactate levels. Most of the
PD patients were continuously taking medication to reduce the
movement disorder. Whether or not these medications can alter the
brain metabolism and how long it would be for the neuronal
metabolism to return to the baseline level after withdrawal of the
medication is unclear. Although we would like to examine naive
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patients without any interference of the drug medication, it is very
difficult practically for ethical reasons, due to the possible
uncomfortable and disabling side effects patients may suffer during
the medication off period. Finally we can ask if there are any clinical
applications of this technique. Can we use 'H-MRS as a diagnostic
tool for early detection of Parkinson's disease? Can it be an
important clinical tool to investigate possible therapeutic
interventions? Since PD is a disease associated with aging, and many
elderly persons may suffer neuronal problems due to natural aging
and Alzheimer's disease, it is possible that the detection of a small
lactate elevation may be associated with other neuronal conditions
rather than PD. It is known that PD symptoms don't show up unless
more than 80% of the dopaminergic innervation in the striatum is
lost [5,6,7]. Thus, the high lactate level in PD patients may only
indicate the near completion of the neuronal degenerative process
but not be present as an early symptomatic sign. However, it may be
of use to measure lactate for aid in the evaluation of possible
therapies by estimating the lactate levels pre- and post- medication;
using perhaps electron transport chain cofactors such as CoQ10.
Furthermore, the lactate level may provide a way to help to
understand the striatal function in PD patients. Under certain
physiological challenges, PD brains may have greater difficulty in
providing enough energy to perform tasks, and thus the lactate level
during neuronal stimulation may be different than normal subjects.
This hypothesis remains to be investigated for future studies. For
instance, Scholz et. al. [17] has shown several motor tasks which will
activate basal ganglia in fMRI studies in the normal controls. One can
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monitor lactate level before, during, and after the motor tasks in
both PD patients and normal controls. In other words, one can
combine motor tasks and functional spectroscopy to evaluate the
response of the basal ganglia under possible energetic stress
postulated to occur in PD.
Validation of usini pharmacological MRI (DhMRI) to assess the
donaminergic neuronal activity
PD is the neurodegenerative disease associated with dysfunction in
energy respiration and dopaminergic innervation in the striatum
[5,6,7]. To better understand the dopaminergic functions in PD, we
used functional MRI with pharmacological stimulation to probe the
dopaminergic system (phMRI). Unlike positron emission tomography
(PET) or autoradiography, this phMRI technique provides a
possibility to examine the same animals longitudinally (better
temporal resolution). The phMRI technique also provides better
spatial resolution when compared to PET. In this thesis, we used D-
amphetamine [18] and CFT [19,20] as our specific probes. Both
ligands can increase the synaptic dopamine concentration transiently.
In order to validate that the phMRI response to the stimulation of D-
amphetamine or CFT is truly linked to the dopaminergic system, we
have to answer two questions:
1) Can we detect the metabolic response to direct neurotransmitter
stimulation by using fMRI?
2) Is this fMRI response specific to a neurotransmitter system?
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To answer these questions, we designed experiments which showed
1) the BOLD signal changes differed from the blood pCO2 and global
blood pressure changes, 2) phMRI responses are regionally specific to
those brain areas with highest dopaminergic innervation, 3) the
phMRI responses correlated well with the "C-CFT binding maps
obtained via PET, 4) the phMRI time courses correlated with the
extracellular dopamine release assessed by microdialysis.
Further to verify that the phMRI responses were truly linked to the
dopaminergic system, we tested this technique on 3 groups of
animals-normal control rats, unilaterally dopaminergic denervated
rats, and dopamine fetal cell transplanted rats. We demonstrated
that the phMRI responses were symmetric in the normal control rats,
unilaterally ablated in the dopaminergically denervated striatum,
and later restored at the graft site in the dopamine fetal cell
transplanted rats.
Although the results from our phMRI experiments strongly suggest
that the phMRI responses are linked to the dopaminergic system, we
are still not clear what caused the BOLD or rCBV changes. Does
amphetamine or CFT modulate mainly the Dl or D2 receptor system
[21,22]? Do the positive BOLD signal changes represent excitatory or
inhibitory neuronal activity? Is the effect mainly on the presynaptic
side or the postsynaptic side? Can the modulation of the
dopaminergic system induce alterations in other neurotransmitter
systems such as serotonin [23,24], GABA [25], or glutamate [25,
26] as well? Is this phMRI response associated with any alteration in
the gene expression such as c-fos [27,28]? Are there any clinical
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application of this techniques? To continue investigating these
question, we may need to modulate the fMRI signals by combining
various agonists and/or antagonists. Pre- or post-treatment of DI/D2
agonists or antagonists with the amphetamine or CFT stimulation in
phMRI experiments may help us to monitor to these two major
dopamine receptor systems. We can also monitor the phMRI
response to pure Dl or D2 agonists/antagonists stimulation to see
whether or not we can obtain similar phMRI response as in the
amphetamine/CFT cases. This can help us to understand the phMRI
signal changes corresponding to excitatory or inhibitory neuronal
activity. One of the advantages of using this pure D1/D2 stimulation
protocol is that we can again correlate the spatial distribution of the
phMRI responses to the binding maps obtained via PET [29]. The
gene responses to stimulation in the dopaminergic system has been a
popular topic recently. Scientists have been trying to investigate
various mRNA responses to drug stimulation such as cocaine and
amphetamine. The c-fos gene has been drawing a lot of attention due
to its instant response to cocaine or amphetamine[30,31]. Histological
studies showed that c-fos expression increases in the dorsal lateral
striatum after the D-amphetamine stimulation [32], which reflects
the spatial distribution of the phMRI response quite well. Whether
or not the phMRI response is due to the increase in c-fos expression
or simply reflects the dopaminergic innervation needs further
investigation. Antisense oligonucleotides have been found to
eliminate the c-fos expression [33] and one can possibly combine the
phMRI amphetamine study with the intrastriatal injection of
antisense oligonucleotides to reveal the role of c-fos in the phMRI
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signal changes. Although all of our 6-OHDA lesioned animals passed
the behavioral test for at least 90% dopaminergic denervation in the
striatum unilaterally, the difference of the phMRI responses in the
two striata (when calculated as percent striatum activated), however,
is only about 40% instead of 90%. Castaneda et. al. [34] showed great
variance in the release of dopamine under the condition of over 90%
loss of the striatal dopamine terminals (figure 3 in ref. 7). Our
phMRI measurement may reflect the real quantity of dopamine
released instead of the number of intact dopaminergic terminals in
the striatum. If we can build the linkage between the phMRI
response and the dopaminergic function quantitatively, the phMRI
technique may help 1) to detect the early loss of dopaminergic
innervation in the elderly brain before any clinical indication of PD
symptoms, 2) to determine the successful sprouting rate of the
transplanted fetal cells over time when neuronal transplantation is
performed on PD patients.
Conclusions
The data presented in this thesis demonstrate the ability of magnetic
resonance techniques to explore various aspects of the
neurodegenerative process. We have demonstrated the ability of 'H-
MRS to investigate the striatal metabolite state in the PD brain. We
have found that the lactate levels in PD patients support the
hypothesis of energy impairment. We also demonstrated the ability
of phMRI to asses neuronal activity. This phMRI technique may not
only help to explore the etiology of PD but also to assess the
functions of various neurotransmitter systems in both normal and
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disease states. We believe the techniques presented in this thesis
have great potential to furnish information that could possibly
monitor treatment strategies and improve the care of patients
suffering from neurodegenerative diseases.
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